{ "instance": { "dmtk-10k_20211231.htm": { "axisCustom": 0, "axisStandard": 31, "contextCount": 358, "dts": { "calculationLink": { "local": [ "dmtk-20211231_cal.xml" ] }, "definitionLink": { "local": [ "dmtk-20211231_def.xml" ] }, "inline": { "local": [ "dmtk-10k_20211231.htm" ] }, "labelLink": { "local": [ "dmtk-20211231_lab.xml" ] }, "presentationLink": { "local": [ "dmtk-20211231_pre.xml" ] }, "schema": { "local": [ "dmtk-20211231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" ] } }, "elementCount": 669, "entityCount": 1, "hidden": { "http://dermtech.com/20211231": 3, "http://fasb.org/us-gaap/2021-01-31": 63, "http://xbrl.sec.gov/dei/2021q4": 5, "total": 71 }, "keyCustom": 97, "keyStandard": 421, "memberCustom": 54, "memberStandard": 35, "nsprefix": "dmtk", "nsuri": "http://dermtech.com/20211231", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentPeriodEndDate", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Cover Page", "role": "http://dermtech.com/20211231/taxonomy/role/DocumentCoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentPeriodEndDate", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100090 - Disclosure - Balance Sheet Details", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetails", "shortName": "Balance Sheet Details", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100100 - Disclosure - Debt", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureDebt", "shortName": "Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100110 - Disclosure - Convertible Preferred Stock and Stockholders' Equity", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquity", "shortName": "Convertible Preferred Stock and Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100120 - Disclosure - Income Taxes", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100130 - Disclosure - Leases, Commitments and Contingencies", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingencies", "shortName": "Leases, Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100140 - Disclosure - Retirement Plan", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureRetirementPlan", "shortName": "Retirement Plan", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100150 - Disclosure - Related Party Transactions", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100160 - Disclosure - Subsequent Events", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureSubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "dmtk:NatureOfOperationsPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100170 - Disclosure - The Company and a Summary of its Significant Accounting Policies (Policies)", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesPolicies", "shortName": "The Company and a Summary of its Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "dmtk:NatureOfOperationsPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100180 - Disclosure - The Company and a Summary of its Significant Accounting Policies (Tables)", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesTables", "shortName": "The Company and a Summary of its Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100010 - Statement - Consolidated Balance Sheets", "role": "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20211231", "decimals": "-3", "lang": null, "name": "us-gaap:MarketableSecuritiesCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100190 - Disclosure - Balance Sheet Details (Tables)", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsTables", "shortName": "Balance Sheet Details (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100200 - Disclosure - Convertible Preferred Stock and Stockholders' Equity (Tables)", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityTables", "shortName": "Convertible Preferred Stock and Stockholders' Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100210 - Disclosure - Income Taxes (Tables)", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsDisclosureTextBlock", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "dmtk:ScheduleOfLongTermFinanceLeaseObligationsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100220 - Disclosure - Leases, Commitments and Contingencies (Tables)", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesTables", "shortName": "Leases, Commitments and Contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsDisclosureTextBlock", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "dmtk:ScheduleOfLongTermFinanceLeaseObligationsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "p", "dmtk:NatureOfOperationsPolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityReverseStockSplit", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100230 - Disclosure - The Company and a Summary of its Significant Accounting Policies - Additional Information (Details)", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails", "shortName": "The Company and a Summary of its Significant Accounting Policies - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "dmtk:NatureOfOperationsPolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityReverseStockSplit", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20201231", "decimals": "-3", "first": true, "lang": null, "name": "dmtk:WarrantLiabilityNonCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100240 - Disclosure - The Company and a Summary of its Significant Accounting Policies - Summary of Impact of Consolidated Balance Sheets from Adjustment (Details)", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfImpactOfConsolidatedBalanceSheetsFromAdjustmentDetails", "shortName": "The Company and a Summary of its Significant Accounting Policies - Summary of Impact of Consolidated Balance Sheets from Adjustment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20201231", "decimals": "-3", "first": true, "lang": null, "name": "dmtk:WarrantLiabilityNonCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueAdjustmentOfWarrants", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100250 - Disclosure - The Company and a Summary of its Significant Accounting Policies - Summary of Impact of Consolidated Statements of Operations from Adjustment (Details)", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfImpactOfConsolidatedStatementsOfOperationsFromAdjustmentDetails", "shortName": "The Company and a Summary of its Significant Accounting Policies - Summary of Impact of Consolidated Statements of Operations from Adjustment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_srtRestatementAxis_srtScenarioPreviouslyReportedMember_20200101_20201231", "decimals": "-3", "lang": null, "name": "us-gaap:NonoperatingIncomeExpense", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100260 - Disclosure - The Company and a Summary of its Significant Accounting Policies - Summary of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails", "shortName": "The Company and a Summary of its Significant Accounting Policies - Summary of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20181231", "decimals": "-3", "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100270 - Disclosure - The Company and a Summary of its Significant Accounting Policies - Schedule of Revenues Disaggregated by Revenue Source (Details)", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesScheduleOfRevenuesDisaggregatedByRevenueSourceDetails", "shortName": "The Company and a Summary of its Significant Accounting Policies - Schedule of Revenues Disaggregated by Revenue Source (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfProductInformationTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_srtProductOrServiceAxis_dmtkAssayRevenuePayorAMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20210101_20211231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unitRef": "U_xbrlipure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100280 - Disclosure - The Company and a Summary of its Significant Accounting Policies - Summary of Percentages of Total Revenue or Accounts Receivable for Third Party Payers and Pharmaceutical Customers (Details)", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfPercentagesOfTotalRevenueOrAccountsReceivableForThirdPartyPayersAndPharmaceuticalCustomersDetails", "shortName": "The Company and a Summary of its Significant Accounting Policies - Summary of Percentages of Total Revenue or Accounts Receivable for Third Party Payers and Pharmaceutical Customers (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R3": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20211231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "U_iso4217USD_xbrlishares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100020 - Statement - Consolidated Balance Sheets (Parenthetical)", "role": "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "us-gaap:CommonStockSharesIssued", "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20211231", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfProductInformationTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_srtProductOrServiceAxis_dmtkAssayRevenuePayorAMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20210101_20211231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unitRef": "U_xbrlipure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100290 - Disclosure - The Company and a Summary of its Significant Accounting Policies - Summary of Percentages of Total Revenue or Accounts Receivable for Third Party Payers and Pharmaceutical Customers (Parenthetical) (Details)", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfPercentagesOfTotalRevenueOrAccountsReceivableForThirdPartyPayersAndPharmaceuticalCustomersParentheticalDetails", "shortName": "The Company and a Summary of its Significant Accounting Policies - Summary of Percentages of Total Revenue or Accounts Receivable for Third Party Payers and Pharmaceutical Customers (Parenthetical) (Details)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "us-gaap:ConcentrationRiskPercentage1", "us-gaap:ConcentrationRiskPercentage1", "us-gaap:ConcentrationRiskPercentage1", "us-gaap:ConcentrationRiskPercentage1", "us-gaap:ConcentrationRiskPercentage1", "span", "span", "span", "span", "span", "p", "us-gaap:ScheduleOfProductInformationTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_srtProductOrServiceAxis_dmtkAssayRevenuePayorAMember_srtRangeAxis_srtMaximumMember_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_20190101_20191231", "decimals": "INF", "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20211231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RevenueRemainingPerformanceObligation", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100300 - Disclosure - The Company and a Summary of its Significant Accounting Policies - Additional Information (Details 1)", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails1", "shortName": "The Company and a Summary of its Significant Accounting Policies - Additional Information (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20211231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RevenueRemainingPerformanceObligation", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_us-gaapPlanNameAxis_dmtkTwoThousandTwentyEmployeeStockPurchasePlanMember_20200101_20201231", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100310 - Disclosure - The Company and a Summary of its Significant Accounting Policies - Assumptions Used to Determine Fair Value of Each Option on Date of Grant Issued (Details)", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAssumptionsUsedToDetermineFairValueOfEachOptionOnDateOfGrantIssuedDetails", "shortName": "The Company and a Summary of its Significant Accounting Policies - Assumptions Used to Determine Fair Value of Each Option on Date of Grant Issued (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_us-gaapPlanNameAxis_dmtkTwoThousandTwentyEmployeeStockPurchasePlanMember_20200101_20201231", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" } }, "R33": { "firstAnchor": null, "groupType": "disclosure", "isDefault": "false", "longName": "100320 - Disclosure - The Company and a Summary of its Significant Accounting Policies - Assumptions Used to Calculate Fair Value of Warrant Liability Using Black-Scholes-Merton Valuation Model (Details)", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAssumptionsUsedToCalculateFairValueOfWarrantLiabilityUsingBlackScholesMertonValuationModelDetails", "shortName": "The Company and a Summary of its Significant Accounting Policies - Assumptions Used to Calculate Fair Value of Warrant Liability Using Black-Scholes-Merton Valuation Model (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R34": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RestrictedCashNoncurrent", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100330 - Disclosure - The Company and a Summary of its Significant Accounting Policies - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "shortName": "The Company and a Summary of its Significant Accounting Policies - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20211231", "decimals": "-3", "lang": null, "name": "us-gaap:CashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_dmtkWarrantLiabilityMember_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100340 - Disclosure - The Company and a Summary of its Significant Accounting Policies - Summary of Changes in Fair Value of Level 3 Liabilities (Details)", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfChangesInFairValueOfLevel3LiabilitiesDetails", "shortName": "The Company and a Summary of its Significant Accounting Policies - Summary of Changes in Fair Value of Level 3 Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_dmtkWarrantLiabilityMember_20191231", "decimals": "-3", "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100350 - Disclosure - Balance Sheet Details - Schedule of Short-Term Marketable Securities (Details)", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfShortTermMarketableSecuritiesDetails", "shortName": "Balance Sheet Details - Schedule of Short-Term Marketable Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20211231", "decimals": "-5", "first": true, "lang": null, "name": "dmtk:EstimatedMarketValueOfDebtSecuritiesWithContractualMaturitiesOfLessThan12Months", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100360 - Disclosure - Balance Sheet Details - Additional Information (Details)", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsAdditionalInformationDetails", "shortName": "Balance Sheet Details - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20211231", "decimals": "-5", "first": true, "lang": null, "name": "dmtk:EstimatedMarketValueOfDebtSecuritiesWithContractualMaturitiesOfLessThan12Months", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "dmtk:ScheduleOfPrepaidExpensesAndPropertyAndEquipmentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PrepaidInsurance", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100370 - Disclosure - Balance Sheet Details - Schedule of Prepaid Expenses and PP&E (Details)", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndPPEDetails", "shortName": "Balance Sheet Details - Schedule of Prepaid Expenses and PP&E (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "dmtk:ScheduleOfPrepaidExpensesAndPropertyAndEquipmentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PrepaidInsurance", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccruedVacationCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100380 - Disclosure - Balance Sheet Details - Schedule of Accrued Compensation and Accrued Liabilities (Details)", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfAccruedCompensationAndAccruedLiabilitiesDetails", "shortName": "Balance Sheet Details - Schedule of Accrued Compensation and Accrued Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AccruedVacationCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100030 - Statement - Consolidated Statements of Operations", "role": "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations", "shortName": "Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210111_20210111", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ProceedsFromIssuanceOfCommonStock", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100390 - Disclosure - Debt - Additional Information (Details)", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "shortName": "Debt - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20190829_20190829", "decimals": "INF", "lang": null, "name": "us-gaap:DebtConversionConvertedInstrumentSharesIssued1", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20211231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100400 - Disclosure - Convertible Preferred Stock and Stockholders Equity - Additional Information (Details)", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "shortName": "Convertible Preferred Stock and Stockholders Equity - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20211231", "decimals": "INF", "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_us-gaapAwardTypeAxis_us-gaapEmployeeStockMember_20201231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100410 - Disclosure - Convertible Preferred Stock and Stockholders Equity - Summary of Stock Options Transactions (Details)", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfStockOptionsTransactionsDetails", "shortName": "Convertible Preferred Stock and Stockholders Equity - Summary of Stock Options Transactions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_us-gaapAwardTypeAxis_us-gaapEmployeeStockMember_20210101_20211231", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20201231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100420 - Disclosure - Convertible Preferred Stock and Stockholders Equity - Summary of Restricted Stock Units Award Transactions (Details)", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfRestrictedStockUnitsAwardTransactionsDetails", "shortName": "Convertible Preferred Stock and Stockholders Equity - Summary of Restricted Stock Units Award Transactions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20210101_20211231", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfStockByClassTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20211231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100430 - Disclosure - Convertible Preferred Stock and Stockholders Equity - Summary of Common Stock Reserved for Future Issuance (Detail)", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetail", "shortName": "Convertible Preferred Stock and Stockholders Equity - Summary of Common Stock Reserved for Future Issuance (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfStockByClassTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_us-gaapAwardTypeAxis_dmtkWarrantsToPurchaseCommonStockMember_20211231", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R45": { "firstAnchor": null, "groupType": "disclosure", "isDefault": "false", "longName": "100440 - Disclosure - Convertible Preferred Stock and Stockholders Equity - Summary of Common Stock Reserved for Future Issuance (Parenthetical) (Details)", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceParentheticalDetails", "shortName": "Convertible Preferred Stock and Stockholders Equity - Summary of Common Stock Reserved for Future Issuance (Parenthetical) (Details)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R46": { "firstAnchor": { "ancestors": [ "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unitRef": "U_xbrlipure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100450 - Disclosure - Income Taxes - Additional Information (Details)", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails", "shortName": "Income Taxes - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:LiabilityForUncertainTaxPositionsCurrent", "us-gaap:LiabilityForUncertainTaxPositionsCurrent", "p", "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20211231", "decimals": "INF", "lang": null, "name": "us-gaap:LiabilityForUncertainTaxPositionsCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unitRef": "U_xbrlipure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100460 - Disclosure - Income Taxes - Schedule of Reconciliation of Income Tax Rate (Details)", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxRateDetails", "shortName": "Income Taxes - Schedule of Reconciliation of Income Tax Rate (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": "3", "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100470 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities from Federal and State Income Taxes (Details)", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesFromFederalAndStateIncomeTaxesDetails", "shortName": "Income Taxes - Schedule of Deferred Tax Assets and Liabilities from Federal and State Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsDisclosureTextBlock", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": "2", "first": true, "lang": null, "name": "dmtk:PercentageOfUsefulLivesOfAssets", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100480 - Disclosure - Leases, Commitments and Contingencies - Additional Information (Details)", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails", "shortName": "Leases, Commitments and Contingencies - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsDisclosureTextBlock", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": "2", "first": true, "lang": null, "name": "dmtk:PercentageOfUsefulLivesOfAssets", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100040 - Statement - Consolidated Statements of Comprehensive Loss", "role": "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss", "shortName": "Consolidated Statements of Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": "-3", "lang": null, "name": "us-gaap:ComprehensiveIncomeNetOfTax", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "us-gaap:CommitmentsDisclosureTextBlock", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FinanceLeaseLiabilityPaymentsDue", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100490 - Disclosure - Leases, Commitments and Contingencies - Schedule of Long Term Finance Lease Obligations (Details)", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfLongTermFinanceLeaseObligationsDetails", "shortName": "Leases, Commitments and Contingencies - Schedule of Long Term Finance Lease Obligations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "us-gaap:CommitmentsDisclosureTextBlock", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20211231", "decimals": "-3", "lang": null, "name": "us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100500 - Disclosure - Leases, Commitments and Contingencies - Components of Lease Expense (Details)", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesComponentsOfLeaseExpenseDetails", "shortName": "Leases, Commitments and Contingencies - Components of Lease Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "dmtk:ScheduleOfFutureMinimumRentalPaymentsForOperatingAndCapitalLeasesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100510 - Disclosure - Leases, Commitments and Contingencies - Schedule of Future Minimum Lease Payments Under Operating and Finance Leases (Details)", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails", "shortName": "Leases, Commitments and Contingencies - Schedule of Future Minimum Lease Payments Under Operating and Finance Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "dmtk:ScheduleOfFutureMinimumRentalPaymentsForOperatingAndCapitalLeasesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_us-gaapBusinessAcquisitionAxis_dmtkCowenMember_20210101_20211231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ProceedsFromIssuanceOrSaleOfEquity", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100520 - Disclosure - Leases, Commitments and Contingencie - Additional Information (Details)", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingencieAdditionalInformationDetails", "shortName": "Leases, Commitments and Contingencie - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_us-gaapBusinessAcquisitionAxis_dmtkCowenMember_20210101_20211231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ProceedsFromIssuanceOrSaleOfEquity", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20211231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100530 - Disclosure - Related Party Transactions - Additional Information (Details)", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "shortName": "Related Party Transactions - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": "INF", "lang": null, "name": "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20181231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100050 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)", "role": "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "shortName": "Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_20181231", "decimals": "-3", "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_us-gaapSubsidiarySaleOfStockAxis_dmtkAtTheMarketOfferingMember_20210101_20211231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100060 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)", "role": "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical", "shortName": "Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_us-gaapSubsidiarySaleOfStockAxis_dmtkAtTheMarketOfferingMember_20210101_20211231", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100070 - Statement - Consolidated Statements of Cash Flows", "role": "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100080 - Disclosure - The Company and a Summary of its Significant Accounting Policies", "role": "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPolicies", "shortName": "The Company and a Summary of its Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "dmtk-10k_20211231.htm", "contextRef": "C_0001651944_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 91, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DocumentCoverPage" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r605", "r606", "r607" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm Id", "terseLabel": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DocumentCoverPage" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r605", "r606", "r607" ], "lang": { "en-us": { "role": { "label": "Auditor Location", "terseLabel": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DocumentCoverPage" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r605", "r606", "r607" ], "lang": { "en-us": { "role": { "label": "Auditor Name", "terseLabel": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DocumentCoverPage" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DocumentCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DocumentCoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r605", "r606", "r607" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report", "terseLabel": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DocumentCoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DocumentCoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DocumentCoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DocumentCoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r608" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DocumentCoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DocumentCoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r603" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated By Reference [Text Block]", "terseLabel": "Documents Incorporated by Reference" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DocumentCoverPage" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DocumentCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line2", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DocumentCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DocumentCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DocumentCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DocumentCoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r602" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DocumentCoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DocumentCoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DocumentCoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r602" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DocumentCoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DocumentCoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r602" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DocumentCoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DocumentCoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r616" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DocumentCoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DocumentCoverPage" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r602" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DocumentCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r602" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DocumentCoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r602" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DocumentCoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r602" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DocumentCoverPage" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DocumentCoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r617" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well Known Seasoned Issuer", "terseLabel": "Entity Well Known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DocumentCoverPage" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r605", "r606", "r607" ], "lang": { "en-us": { "role": { "label": "Icfr Auditor Attestation Flag", "terseLabel": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DocumentCoverPage" ], "xbrltype": "booleanItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DocumentCoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r601" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DocumentCoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r604" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DocumentCoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DocumentCoverPage" ], "xbrltype": "tradingSymbolItemType" }, "dmtk_AccountingPronouncementsIssuedButNotYetEffectivePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accounting pronouncements issued but not yet effective.", "label": "Accounting Pronouncements Issued But Not Yet Effective Policy Policy [Text Block]", "terseLabel": "Accounting Pronouncements Issued But Not Yet Effective" } } }, "localname": "AccountingPronouncementsIssuedButNotYetEffectivePolicyPolicyTextBlock", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "dmtk_AccruedBonusAndDeferredCompensationCurrent": { "auth_ref": [], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfAccruedCompensationAndAccruedLiabilitiesDetails": { "order": 10040.0, "parentTag": "us-gaap_EmployeeRelatedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued bonus and deferred compensation, current.", "label": "Accrued Bonus And Deferred Compensation Current", "terseLabel": "Accrued bonus and deferred compensation" } } }, "localname": "AccruedBonusAndDeferredCompensationCurrent", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfAccruedCompensationAndAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_AccruedConsultingServicesCurrent": { "auth_ref": [], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfAccruedCompensationAndAccruedLiabilitiesDetails": { "order": 10010.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued consulting services, current.", "label": "Accrued Consulting Services Current", "terseLabel": "Accrued consulting services" } } }, "localname": "AccruedConsultingServicesCurrent", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfAccruedCompensationAndAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_AdjustmentsToAdditionalPaidInCapitalAssumedInBusinessCombination": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Adjustments to additional paid in capital assumed in business combination.", "label": "Adjustments To Additional Paid In Capital Assumed In Business Combination", "terseLabel": "Additional paid in capital assumed in Business Combination" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalAssumedInBusinessCombination", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "dmtk_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfConvertiblePreferredStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Adjustments to additional paid in capital increase in carrying amount of convertible preferred stock.", "label": "Adjustments To Additional Paid In Capital Increase In Carrying Amount Of Convertible Preferred Stock", "terseLabel": "Issuance of Series A preferred stock at $3,250 per share" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfConvertiblePreferredStock", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "dmtk_AdjustmentsToAdditionalPaidInCapitalIssuanceCostRelatedToRegistration": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Adjustments to additional paid in capital issuance cost related to registration.", "label": "Adjustments To Additional Paid In Capital Issuance Cost Related To Registration", "terseLabel": "Issuance costs in connection with Form?S-1?registration statement" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalIssuanceCostRelatedToRegistration", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "dmtk_AdjustmentsToAdditionalPaidInCapitalIssuanceOfSeriesB1ConvertiblePreferredStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Adjustments to additional paid in capital issuance of series B1 convertible preferred stock.", "label": "Adjustments To Additional Paid In Capital Issuance Of Series B1 Convertible Preferred Stock", "terseLabel": "Issuance of Series B-1 convertible preferred stock" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalIssuanceOfSeriesB1ConvertiblePreferredStock", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "dmtk_AdjustmentsToAdditionalPaidInCapitalIssuanceOfSeriesB2ConvertiblePreferredStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Adjustments to additional paid in capital issuance of series B2 convertible preferred stock.", "label": "Adjustments To Additional Paid In Capital Issuance Of Series B2 Convertible Preferred Stock", "terseLabel": "Issuance of Series B-2 convertible preferred stock" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalIssuanceOfSeriesB2ConvertiblePreferredStock", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "dmtk_AmortizationOfLaboratoryEquipmentAcquiredUnderFinanceLeasesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amortization of laboratory equipment acquired under finance leases.", "label": "Amortization Of Laboratory Equipment Acquired Under Finance Leases [Member]", "terseLabel": "Amortization of Laboratory Equipment Acquired under Finance Leases" } } }, "localname": "AmortizationOfLaboratoryEquipmentAcquiredUnderFinanceLeasesMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_AreaOfBuilding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area of building.", "label": "Area Of Building", "terseLabel": "Area of building" } } }, "localname": "AreaOfBuilding", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "areaItemType" }, "dmtk_AssayMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Assay.", "label": "Assay [Member]", "terseLabel": "Assay Revenue" } } }, "localname": "AssayMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesScheduleOfRevenuesDisaggregatedByRevenueSourceDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "domainItemType" }, "dmtk_AssayRevenuePayorAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Assay Revenue Payor A.", "label": "Assay Revenue Payor A [Member]", "terseLabel": "Assay Revenue Payor A" } } }, "localname": "AssayRevenuePayorAMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfPercentagesOfTotalRevenueOrAccountsReceivableForThirdPartyPayersAndPharmaceuticalCustomersDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfPercentagesOfTotalRevenueOrAccountsReceivableForThirdPartyPayersAndPharmaceuticalCustomersParentheticalDetails" ], "xbrltype": "domainItemType" }, "dmtk_AssayRevenuePayorBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Assay Revenue Payor B.", "label": "Assay Revenue Payor B [Member]", "terseLabel": "Assay Revenue Payor B" } } }, "localname": "AssayRevenuePayorBMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfPercentagesOfTotalRevenueOrAccountsReceivableForThirdPartyPayersAndPharmaceuticalCustomersDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfPercentagesOfTotalRevenueOrAccountsReceivableForThirdPartyPayersAndPharmaceuticalCustomersParentheticalDetails" ], "xbrltype": "domainItemType" }, "dmtk_AssetsHeldUnderFinanceLeasesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Assets held under finance leases.", "label": "Assets Held Under Finance Leases [Member]", "terseLabel": "Assets Recorded under Finance Leases" } } }, "localname": "AssetsHeldUnderFinanceLeasesMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_AtTheMarketOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "At the market offering.", "label": "At The Market Offering [Member]", "terseLabel": "At-The Market Offering", "verboseLabel": "At-The Market Offering" } } }, "localname": "AtTheMarketOfferingMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" ], "xbrltype": "domainItemType" }, "dmtk_AuthorizedForFutureESPPPurchasesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Authorized for future ESPP purchases.", "label": "Authorized For Future E S P P Purchases [Member]", "terseLabel": "Authorized for Future ESPP Purchases" } } }, "localname": "AuthorizedForFutureESPPPurchasesMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetail" ], "xbrltype": "domainItemType" }, "dmtk_AuthorizedForFutureEquityGrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Authorized for future equity grants.", "label": "Authorized For Future Equity Grants [Member]", "terseLabel": "Authorized for Future Equity Grants" } } }, "localname": "AuthorizedForFutureEquityGrantsMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetail" ], "xbrltype": "domainItemType" }, "dmtk_BrotherOfChiefExecutiveOfficerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Brother of chief executive officer.", "label": "Brother Of Chief Executive Officer [Member]", "terseLabel": "Michael Dobak" } } }, "localname": "BrotherOfChiefExecutiveOfficerMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cash paid for amounts included in the measurement of lease liabilities.", "label": "Cash Paid For Amounts Included In Measurement Of Lease Liabilities [Abstract]", "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities" } } }, "localname": "CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesComponentsOfLeaseExpenseDetails" ], "xbrltype": "stringItemType" }, "dmtk_CashlessExerciseOfCommonStockWarrants": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cashless exercise of common stock warrants.", "label": "Cashless Exercise Of Common Stock Warrants", "terseLabel": "Cashless exercise of common stock warrants" } } }, "localname": "CashlessExerciseOfCommonStockWarrants", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "dmtk_ChangeInUnrealizedGainLossOnAvailableForSaleMarketableSecurities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Change in unrealized gain loss on available-for-sale marketable securities.", "label": "Change In Unrealized Gain Loss On Available For Sale Marketable Securities", "terseLabel": "Change in unrealized loss on available-for-sale marketable securities" } } }, "localname": "ChangeInUnrealizedGainLossOnAvailableForSaleMarketableSecurities", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "dmtk_ClassOfWarrantOrRightsIssuedToPurchaseCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class of warrant or rights issued to purchase common stock.", "label": "Class Of Warrant Or Rights Issued To Purchase Common Stock", "terseLabel": "Warrants issued to purchase common stock" } } }, "localname": "ClassOfWarrantOrRightsIssuedToPurchaseCommonStock", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "dmtk_CommitmentsAndContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commitments and contingencies.", "label": "Commitments And Contingencies [Line Items]", "terseLabel": "Commitments And Contingencies [Line Items]" } } }, "localname": "CommitmentsAndContingenciesLineItems", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingencieAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "dmtk_CommitmentsAndContingenciesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commitments and contingencies.", "label": "Commitments And Contingencies [Table]", "terseLabel": "Commitments And Contingencies [Table]" } } }, "localname": "CommitmentsAndContingenciesTable", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingencieAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "dmtk_CommonSharesIssuedUponExerciseOfWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common shares issued upon exercise of warrants.", "label": "Common Shares Issued Upon Exercise Of Warrants", "terseLabel": "Common shares issued upon exercise of warrants" } } }, "localname": "CommonSharesIssuedUponExerciseOfWarrants", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "dmtk_CommonStockOutstandingPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock outstanding percentage.", "label": "Common Stock Outstanding Percentage", "terseLabel": "Common stock outstanding percentage" } } }, "localname": "CommonStockOutstandingPercentage", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "dmtk_ComputerEquipmentGross": { "auth_ref": [], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndPPEDetails": { "order": 10040.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Computer equipment gross.", "label": "Computer Equipment Gross", "terseLabel": "Computer equipment" } } }, "localname": "ComputerEquipmentGross", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndPPEDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_ContractRevenueCustomerAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contract Revenue Customer A.", "label": "Contract Revenue Customer A [Member]", "terseLabel": "Contract Revenue Customer A" } } }, "localname": "ContractRevenueCustomerAMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfPercentagesOfTotalRevenueOrAccountsReceivableForThirdPartyPayersAndPharmaceuticalCustomersDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfPercentagesOfTotalRevenueOrAccountsReceivableForThirdPartyPayersAndPharmaceuticalCustomersParentheticalDetails" ], "xbrltype": "domainItemType" }, "dmtk_ContractRevenueCustomerBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contract revenue customer B.", "label": "Contract Revenue Customer B [Member]", "terseLabel": "Contract Revenue Customer B" } } }, "localname": "ContractRevenueCustomerBMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfPercentagesOfTotalRevenueOrAccountsReceivableForThirdPartyPayersAndPharmaceuticalCustomersDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfPercentagesOfTotalRevenueOrAccountsReceivableForThirdPartyPayersAndPharmaceuticalCustomersParentheticalDetails" ], "xbrltype": "domainItemType" }, "dmtk_ContractRevenueCustomerCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contract revenue customer C.", "label": "Contract Revenue Customer C [Member]", "terseLabel": "Contract Revenue Customer C" } } }, "localname": "ContractRevenueCustomerCMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfPercentagesOfTotalRevenueOrAccountsReceivableForThirdPartyPayersAndPharmaceuticalCustomersDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfPercentagesOfTotalRevenueOrAccountsReceivableForThirdPartyPayersAndPharmaceuticalCustomersParentheticalDetails" ], "xbrltype": "domainItemType" }, "dmtk_ContractRevenueProjectManagementFeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contract revenue project management fees.", "label": "Contract Revenue Project Management Fees [Member]", "terseLabel": "Contract Revenue, Project Management Fees" } } }, "localname": "ContractRevenueProjectManagementFeesMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesScheduleOfRevenuesDisaggregatedByRevenueSourceDetails" ], "xbrltype": "domainItemType" }, "dmtk_ContractRevenueRNAExtractionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contract revenue, RNA extractions.", "label": "Contract Revenue R N A Extractions [Member]", "terseLabel": "Contract Revenue, RNA Extractions" } } }, "localname": "ContractRevenueRNAExtractionsMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesScheduleOfRevenuesDisaggregatedByRevenueSourceDetails" ], "xbrltype": "domainItemType" }, "dmtk_ContractRevenueSmartStickersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contract revenue smart stickers.", "label": "Contract Revenue Smart Stickers [Member]", "terseLabel": "Contract Revenue, Smart Stickers" } } }, "localname": "ContractRevenueSmartStickersMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesScheduleOfRevenuesDisaggregatedByRevenueSourceDetails" ], "xbrltype": "domainItemType" }, "dmtk_ContractualActivitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contract activities.", "label": "Contractual Activities [Member]", "terseLabel": "Contract Revenue" } } }, "localname": "ContractualActivitiesMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "domainItemType" }, "dmtk_ConversionOfPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Conversion of preferred stock.", "label": "Conversion Of Preferred Stock [Member]", "terseLabel": "Conversion of Preferred Stock" } } }, "localname": "ConversionOfPreferredStockMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_CowenLimitedLiabilityCompanyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cowen Limited Liability Company.", "label": "Cowen Limited Liability Company [Member]", "terseLabel": "Cowen and Company LLC" } } }, "localname": "CowenLimitedLiabilityCompanyMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_CowenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cowen.", "label": "Cowen [Member]", "verboseLabel": "Cowen" } } }, "localname": "CowenMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingencieAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_DebtConversionRatioNumberUsedAsNumeratorToDeriveQuotient": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt conversion ratio number used as numerator to derive quotient.", "label": "Debt Conversion Ratio Number Used As Numerator To Derive Quotient", "terseLabel": "Debt Conversion Ratio Number Used As Numerator to Derive Quotient" } } }, "localname": "DebtConversionRatioNumberUsedAsNumeratorToDeriveQuotient", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_DebtDiscountAndDerivativeLiabilityAtIssuanceOfConvertibleNotesPayable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt discount and derivative liability at issuance of convertible notes payable.", "label": "Debt Discount And Derivative Liability At Issuance Of Convertible Notes Payable", "terseLabel": "Debt discount and derivative liability at issuance of convertible notes payable" } } }, "localname": "DebtDiscountAndDerivativeLiabilityAtIssuanceOfConvertibleNotesPayable", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "dmtk_DeferredTaxAssetsDepreciationAndAmortization": { "auth_ref": [], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesFromFederalAndStateIncomeTaxesDetails": { "order": 10090.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred tax assets depreciation and amortization.", "label": "Deferred Tax Assets Depreciation And Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DeferredTaxAssetsDepreciationAndAmortization", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesFromFederalAndStateIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_DeferredTaxAssetsLiabilitiesBeforeValuationAllowance": { "auth_ref": [], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesFromFederalAndStateIncomeTaxesDetails": { "order": 10010.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred tax assets liabilities before valuation allowance.", "label": "Deferred Tax Assets Liabilities Before Valuation Allowance", "totalLabel": "Net deferred tax assets before valuation allowance" } } }, "localname": "DeferredTaxAssetsLiabilitiesBeforeValuationAllowance", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesFromFederalAndStateIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_DeferredTaxAssetsOperatingLeaseLiabilities": { "auth_ref": [], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesFromFederalAndStateIncomeTaxesDetails": { "order": 10120.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred tax assets operating lease liabilities.", "label": "Deferred Tax Assets Operating Lease Liabilities", "terseLabel": "Operating lease liability" } } }, "localname": "DeferredTaxAssetsOperatingLeaseLiabilities", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesFromFederalAndStateIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_DeferredTaxLiabilitiesDepreciationAndAmortization": { "auth_ref": [], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesFromFederalAndStateIncomeTaxesDetails": { "order": 10050.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred tax liabilities depreciation and amortization.", "label": "Deferred Tax Liabilities Depreciation And Amortization", "negatedLabel": "Depreciation and amortization" } } }, "localname": "DeferredTaxLiabilitiesDepreciationAndAmortization", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesFromFederalAndStateIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets": { "auth_ref": [], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesFromFederalAndStateIncomeTaxesDetails": { "order": 10060.0, "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred tax liabilities operating lease right-of-use assets,", "label": "Deferred Tax Liabilities Operating Lease Right Of Use Assets", "negatedLabel": "Operating lease right-of-use assets" } } }, "localname": "DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesFromFederalAndStateIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_DeferredUnderwritingFeeEquityPayableIfEquityFinancingLimitNotRaised": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred underwriting fee equity payable if equity financing limit not raised.", "label": "Deferred Underwriting Fee Equity Payable If Equity Financing Limit Not Raised", "terseLabel": "Deferred underwriting fee equity payable if equity financing limit not raised" } } }, "localname": "DeferredUnderwritingFeeEquityPayableIfEquityFinancingLimitNotRaised", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingencieAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_DeferredUnderwritingFeesCurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred underwriting fees current.", "label": "Deferred Underwriting Fees Current", "terseLabel": "Underwriting fees" } } }, "localname": "DeferredUnderwritingFeesCurrent", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingencieAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_DenominatorForCalculatingCapitalizationValueForPricePerShare": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Denominator for calculating capitalization value for price per share.", "label": "Denominator For Calculating Capitalization Value For Price Per Share", "terseLabel": "Denominator for calculating capitalization value for price per share" } } }, "localname": "DenominatorForCalculatingCapitalizationValueForPricePerShare", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_DermTechOperationsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "DermTech Operations, Inc.", "label": "Derm Tech Operations Inc [Member]", "terseLabel": "DermTech,Inc." } } }, "localname": "DermTechOperationsIncMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_EVERSANALifeScienceServicesLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "EVERSANA Life Science Services, LLC.", "label": "E V E R S A N A Life Science Services L L C [Member]", "terseLabel": "EVERSANA" } } }, "localname": "EVERSANALifeScienceServicesLLCMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_EffectiveIncomeTaxRateReconciliationPermanentItems": { "auth_ref": [], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxRateDetails": { "order": 10030.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Effective income tax rate reconciliation permanent items.", "label": "Effective Income Tax Rate Reconciliation Permanent Items", "terseLabel": "Permanent items" } } }, "localname": "EffectiveIncomeTaxRateReconciliationPermanentItems", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "dmtk_EquityIncentivePlanOptionTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity incentive plan option term.", "label": "Equity Incentive Plan Option Term", "terseLabel": "Term of the option" } } }, "localname": "EquityIncentivePlanOptionTerm", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "dmtk_EstimatedMarketValueOfDebtSecuritiesWithContractualMaturitiesOfLessThan12Months": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Estimated market value of debt securities with contractual maturities of less than 12 months.", "label": "Estimated Market Value Of Debt Securities With Contractual Maturities Of Less Than12 Months", "terseLabel": "Estimated market value of debt securities with contractual maturities of less than 12 months" } } }, "localname": "EstimatedMarketValueOfDebtSecuritiesWithContractualMaturitiesOfLessThan12Months", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_EstimatedMarketValueOfRemainingDebtSecuritiesWithContractualMaturitiesOfUpTo14Months": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Estimated market value of remaining debt securities with contractual maturities of up to 14 months.", "label": "Estimated Market Value Of Remaining Debt Securities With Contractual Maturities Of Up To14 Months", "terseLabel": "Estimated market value of remaining debt securities with contractual maturities of up to 14 months" } } }, "localname": "EstimatedMarketValueOfRemainingDebtSecuritiesWithContractualMaturitiesOfUpTo14Months", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_EstimatedMarketValueOfRemainingDebtSecuritiesWithContractualMaturitiesOfUpTo23Months": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Estimated market value of remaining debt securities with contractual maturities of up to 23 months.", "label": "Estimated Market Value Of Remaining Debt Securities With Contractual Maturities Of Up To23 Months", "terseLabel": "Estimated market value of remaining debt securities with contractual maturities of up to 23 months" } } }, "localname": "EstimatedMarketValueOfRemainingDebtSecuritiesWithContractualMaturitiesOfUpTo23Months", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfWarrantLiabilityFromExerciseOfPrivateSpacWarrants": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, measurement with unobservable inputs reconciliation, recurring basis, liability derecognition of warrant liability from exercise of private spac warrants.", "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Derecognition Of Warrant Liability From Exercise Of Private Spac Warrants", "negatedLabel": "Derecognition of warrant liability from exercise of Private SPAC Warrants" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityDerecognitionOfWarrantLiabilityFromExerciseOfPrivateSpacWarrants", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfChangesInFairValueOfLevel3LiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationOfWarrantLiabilityDueToPrivateSpacWarrantsNotHeldByOriginalHolder": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, measurement with unobservable inputs reconciliation, recurring basis, liability reclassification of warrant liability due to private spac warrants not held by original holder.", "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Reclassification Of Warrant Liability Due To Private Spac Warrants Not Held By Original Holder", "negatedLabel": "Reclassification of warrant liability due to Private SPAC Warrants not held by original holder" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationOfWarrantLiabilityDueToPrivateSpacWarrantsNotHeldByOriginalHolder", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfChangesInFairValueOfLevel3LiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_FinanceLeaseCost": { "auth_ref": [], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesComponentsOfLeaseExpenseDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Finance lease cost.", "label": "Finance Lease Cost", "totalLabel": "Total finance lease cost" } } }, "localname": "FinanceLeaseCost", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesComponentsOfLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_FinanceLeaseCostsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Finance lease cost.", "label": "Finance Lease Costs [Abstract]", "terseLabel": "Finance lease cost" } } }, "localname": "FinanceLeaseCostsAbstract", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesComponentsOfLeaseExpenseDetails" ], "xbrltype": "stringItemType" }, "dmtk_GrossProceedsFromIssuanceOfCommonStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross proceeds from issuance of common stock.", "label": "Gross Proceeds From Issuance Of Common Stock", "terseLabel": "Gross proceeds from issuance of common stock" } } }, "localname": "GrossProceedsFromIssuanceOfCommonStock", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_GrossProceedsFromOfferingBeforeDeductingUnderwritingDiscountsAndCommissionsAndOtherOfferingExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross proceeds from offering, before deducting underwriting discounts and commissions and other offering expenses.", "label": "Gross Proceeds From Offering Before Deducting Underwriting Discounts And Commissions And Other Offering Expenses", "terseLabel": "Gross proceeds from offering, before deducting underwriting discounts and commissions and other offering expenses" } } }, "localname": "GrossProceedsFromOfferingBeforeDeductingUnderwritingDiscountsAndCommissionsAndOtherOfferingExpenses", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_IncentiveAndNonQualifiedStockOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Incentive and non-qualified stock options.", "label": "Incentive And Non Qualified Stock Options [Member]", "terseLabel": "Incentive and Non-qualified Stock Options" } } }, "localname": "IncentiveAndNonQualifiedStockOptionsMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_IncentiveAndNonStatutoryStockOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Incentive and non-statutory stock options.", "label": "Incentive And Non Statutory Stock Options [Member]", "terseLabel": "Incentive and Non-statutory Stock Options" } } }, "localname": "IncentiveAndNonStatutoryStockOptionsMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_IncentiveStockOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Incentive stock options.", "label": "Incentive Stock Options [Member]", "terseLabel": "Incentive Stock Options" } } }, "localname": "IncentiveStockOptionsMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_IncreaseDecreaseInAccountsPayableAndAccruedCompensation": { "auth_ref": [], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10390.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase decrease in accounts payable and accrued compensation.", "label": "Increase Decrease In Accounts Payable And Accrued Compensation", "terseLabel": "Accounts payable and accrued compensation" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedCompensation", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "dmtk_IncreaseDecreaseInAccruedLiabilitiesAndDeferredRevenue": { "auth_ref": [], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10400.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in accrued liabilities and deferred revenue.", "label": "Increase Decrease In Accrued Liabilities And Deferred Revenue", "terseLabel": "Accrued liabilities and deferred revenue" } } }, "localname": "IncreaseDecreaseInAccruedLiabilitiesAndDeferredRevenue", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "dmtk_IncreaseDecreaseInStockIssuanceCosts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase decrease in stock issuance costs.", "label": "Increase Decrease In Stock Issuance Costs", "negatedLabel": "Decrease in issuance costs" } } }, "localname": "IncreaseDecreaseInStockIssuanceCosts", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_IncreaseInTenantImprovementAllowance": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase in tenant improvement allowance.", "label": "Increase In Tenant Improvement Allowance", "terseLabel": "Increase in tenant improvement allowance" } } }, "localname": "IncreaseInTenantImprovementAllowance", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_IssuanceOfCommonStockInLitigationSettlement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issuance of common stock in litigation settlement.", "label": "Issuance Of Common Stock In Litigation Settlement", "terseLabel": "Issuance of common stock in litigation settlement" } } }, "localname": "IssuanceOfCommonStockInLitigationSettlement", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "dmtk_KilroyRealtyLPMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Kilroy Realty, L.P.", "label": "Kilroy Realty L P [Member]", "terseLabel": "Kilroy Realty, L.P" } } }, "localname": "KilroyRealtyLPMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_LeaseCommencementDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease commencement date.", "label": "Lease Commencement Date", "terseLabel": "Lease commencement date" } } }, "localname": "LeaseCommencementDate", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "dmtk_LeaseTermExtendPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease term extend period.", "label": "Lease Term Extend Period", "terseLabel": "Extend lease term" } } }, "localname": "LeaseTermExtendPeriod", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "dmtk_LifeSciMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "LifeSci.", "label": "Life Sci [Member]", "terseLabel": "LifeSci Capital LLC" } } }, "localname": "LifeSciMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "dmtk_ManagementWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Management warrants.", "label": "Management Warrants [Member]", "terseLabel": "Management Warrants" } } }, "localname": "ManagementWarrantsMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_MergerConsiderationDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Merger consideration description.", "label": "Merger Consideration Description", "terseLabel": "Description of merger consideration" } } }, "localname": "MergerConsiderationDescription", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "dmtk_MergerConsiderationMaximumPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Merger consideration maximum price per share.", "label": "Merger Consideration Maximum Price Per Share", "terseLabel": "Merger consideration maximum price per share" } } }, "localname": "MergerConsiderationMaximumPricePerShare", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "dmtk_NatureOfOperationsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Nature of operations.", "label": "Nature Of Operations Policy [Text Block]", "terseLabel": "Nature of Operations" } } }, "localname": "NatureOfOperationsPolicyTextBlock", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "dmtk_NetChangeInNetCashUsedInOperatingActivities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Net change in net cash used in operating activities.", "label": "Net Change In Net Cash Used In Operating Activities", "terseLabel": "Net change in net cash used in operating activities" } } }, "localname": "NetChangeInNetCashUsedInOperatingActivities", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_NumberOfRevenueStreams": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of revenue streams.", "label": "Number Of Revenue Streams", "terseLabel": "Number of revenue streams" } } }, "localname": "NumberOfRevenueStreams", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "dmtk_NumberOfWarrantsEntitleHolderToPurchaseOneShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants entitle holder to purchase one share.", "label": "Number Of Warrants Entitle Holder To Purchase One Share", "terseLabel": "Number of warrants entitle holder to purchase one share" } } }, "localname": "NumberOfWarrantsEntitleHolderToPurchaseOneShare", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceParentheticalDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "dmtk_OperatingAndCapitalLeaseLiabilityPaymentsDue": { "auth_ref": [], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating and capital lease liability payments due.", "label": "Operating And Capital Lease Liability Payments Due", "totalLabel": "Total future minimum lease payments" } } }, "localname": "OperatingAndCapitalLeaseLiabilityPaymentsDue", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_OperatingAndCapitalLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails": { "order": 10010.0, "parentTag": "dmtk_OperatingAndCapitalLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating and capital lease liability payments due next twelve months.", "label": "Operating And Capital Lease Liability Payments Due Next Twelve Months", "terseLabel": "Total future minimum lease payments due in 2022" } } }, "localname": "OperatingAndCapitalLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_OperatingAndCapitalLeaseLiabilityPaymentsDueThereafter": { "auth_ref": [], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails": { "order": 10060.0, "parentTag": "dmtk_OperatingAndCapitalLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating and capital lease liability payments due thereafter.", "label": "Operating And Capital Lease Liability Payments Due Thereafter", "terseLabel": "Total future minimum lease payments due thereafter" } } }, "localname": "OperatingAndCapitalLeaseLiabilityPaymentsDueThereafter", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_OperatingAndCapitalLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails": { "order": 10050.0, "parentTag": "dmtk_OperatingAndCapitalLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating and capital lease liability payments due year five.", "label": "Operating And Capital Lease Liability Payments Due Year Five", "terseLabel": "Total future minimum lease payments due in 2026" } } }, "localname": "OperatingAndCapitalLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_OperatingAndCapitalLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails": { "order": 10040.0, "parentTag": "dmtk_OperatingAndCapitalLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating and capital lease liability payments due year four.", "label": "Operating And Capital Lease Liability Payments Due Year Four", "terseLabel": "Total future minimum lease payments due in 2025" } } }, "localname": "OperatingAndCapitalLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_OperatingAndCapitalLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails": { "order": 10030.0, "parentTag": "dmtk_OperatingAndCapitalLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating and capital lease liability payments due year three.", "label": "Operating And Capital Lease Liability Payments Due Year Three", "terseLabel": "Total future minimum lease payments due in 2024" } } }, "localname": "OperatingAndCapitalLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_OperatingAndCapitalLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails": { "order": 10020.0, "parentTag": "dmtk_OperatingAndCapitalLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating and capital lease liability payments due year two.", "label": "Operating And Capital Lease Liability Payments Due Year Two", "terseLabel": "Total future minimum lease payments due in 2023" } } }, "localname": "OperatingAndCapitalLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_OperatingLeaseCostAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating lease cost.", "label": "Operating Lease Cost [Abstract]", "terseLabel": "Operating lease cost" } } }, "localname": "OperatingLeaseCostAbstract", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesComponentsOfLeaseExpenseDetails" ], "xbrltype": "stringItemType" }, "dmtk_OperatingLeaseCosts": { "auth_ref": [], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesComponentsOfLeaseExpenseDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Operating lease cost.", "label": "Operating Lease Costs", "totalLabel": "Total operating lease cost" } } }, "localname": "OperatingLeaseCosts", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesComponentsOfLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_OptionsGrantedToShareholderPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Options granted to shareholder, percentage.", "label": "Options Granted To Shareholder Percentage", "terseLabel": "Options granted to shareholder, percentage" } } }, "localname": "OptionsGrantedToShareholderPercentage", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "dmtk_PaymentForDeferredUnderwritingFees": { "auth_ref": [], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10080.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payment for deferred underwriting fees.", "label": "Payment For Deferred Underwriting Fees", "negatedLabel": "Payments of deferred underwriting fees", "terseLabel": "Payments for deferred underwriting fees" } } }, "localname": "PaymentForDeferredUnderwritingFees", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "dmtk_PaymentInConnectionWithRestrictedStockUnitRelease": { "auth_ref": [], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10340.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payment in connection with restricted stock unit release.", "label": "Payment In Connection With Restricted Stock Unit Release", "negatedLabel": "Payment in connection with restricted stock unit release" } } }, "localname": "PaymentInConnectionWithRestrictedStockUnitRelease", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "dmtk_PercentageOfPriceAtSharesPurchased": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of price at shares purchased", "label": "Percentage Of Price At Shares Purchased", "terseLabel": "Percentage of price at shares purchased" } } }, "localname": "PercentageOfPriceAtSharesPurchased", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "dmtk_PercentageOfPricePerShareOfNewStockPaidInQualifiedFinancingByInvestors": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of price per share of new stock paid in qualified financing by investors.", "label": "Percentage Of Price Per Share Of New Stock Paid In Qualified Financing By Investors", "terseLabel": "Percentage of multiplier on price per share of new stock paid in qualified financing by investors" } } }, "localname": "PercentageOfPricePerShareOfNewStockPaidInQualifiedFinancingByInvestors", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "dmtk_PercentageOfUsefulLivesOfAssets": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of useful lives of assets.", "label": "Percentage Of Useful Lives Of Assets", "terseLabel": "Percentage of useful lives of assets" } } }, "localname": "PercentageOfUsefulLivesOfAssets", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "dmtk_PercentageOfWarrantsIssuedInConnectionWithPreferredStockPurchased": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of warrants issued in connection with preferred stock purchased.", "label": "Percentage Of Warrants Issued In Connection With Preferred Stock Purchased", "terseLabel": "Percentage of warrants issued in connection with preferred stock purchased" } } }, "localname": "PercentageOfWarrantsIssuedInConnectionWithPreferredStockPurchased", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "dmtk_PlacementAgentWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Placement agent warrants.", "label": "Placement Agent Warrants [Member]", "terseLabel": "Placement Agent Warrants" } } }, "localname": "PlacementAgentWarrantsMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_PreferredStockDesignatedSharesAuthorizedAndUnissued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred stock designated shares authorized and unissued.", "label": "Preferred Stock Designated Shares Authorized And Unissued", "terseLabel": "Preferred stock designated shares authorized and unissued" } } }, "localname": "PreferredStockDesignatedSharesAuthorizedAndUnissued", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "dmtk_PreferredStockValueOfSharesPurchasedByInvestors": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Preferred stock value of shares purchased by investors.", "label": "Preferred Stock Value Of Shares Purchased By Investors", "terseLabel": "Preferred stock value of shares purchased in single closing" } } }, "localname": "PreferredStockValueOfSharesPurchasedByInvestors", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_PrepaidEmployeeCompensation": { "auth_ref": [], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndPPEDetails": { "order": 10110.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Prepaid employee compensation.", "label": "Prepaid Employee Compensation", "terseLabel": "Prepaid employee compensation" } } }, "localname": "PrepaidEmployeeCompensation", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndPPEDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_PrepaidSoftwareFees": { "auth_ref": [], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndPPEDetails": { "order": 10090.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Prepaid software fees.", "label": "Prepaid Software Fees", "terseLabel": "Prepaid software fees" } } }, "localname": "PrepaidSoftwareFees", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndPPEDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_PrepaidTradeShowsCurrent": { "auth_ref": [], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndPPEDetails": { "order": 10080.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Prepaid trade shows, current.", "label": "Prepaid Trade Shows Current", "terseLabel": "Prepaid trade shows" } } }, "localname": "PrepaidTradeShowsCurrent", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndPPEDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_PrivatePlacementOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Private placement offering.", "label": "Private Placement Offering [Member]", "terseLabel": "Private Placement Offering" } } }, "localname": "PrivatePlacementOfferingMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_PrivateSpecialPurposeAcquisitionCompaniesWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Private special purpose acquisition companies warrants.", "label": "Private Special Purpose Acquisition Companies Warrants [Member]", "terseLabel": "Private SPAC Warrants" } } }, "localname": "PrivateSpecialPurposeAcquisitionCompaniesWarrantsMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_ProceedsFromSaleOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10210.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from sale of marketable securities.", "label": "Proceeds From Sale Of Marketable Securities", "terseLabel": "Sales of marketable securities" } } }, "localname": "ProceedsFromSaleOfMarketableSecurities", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "dmtk_ProceedsReceivedFromCloseOfBusinessCombination": { "auth_ref": [], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10190.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds received from close of business combination.", "label": "Proceeds Received From Close Of Business Combination", "terseLabel": "Proceeds received from close of Business Combination" } } }, "localname": "ProceedsReceivedFromCloseOfBusinessCombination", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "dmtk_PublicFollowOnOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Public follow on offering.", "label": "Public Follow On Offering [Member]", "terseLabel": "Public Follow on Offering" } } }, "localname": "PublicFollowOnOfferingMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "domainItemType" }, "dmtk_PublicOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Public offering.", "label": "Public Offering [Member]", "terseLabel": "Public Offering" } } }, "localname": "PublicOfferingMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_PublicSpecialPurposeAcquisitionCompaniesWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Public special purpose acquisition companies warrants.", "label": "Public Special Purpose Acquisition Companies Warrants [Member]", "terseLabel": "Public SPAC Warrants" } } }, "localname": "PublicSpecialPurposeAcquisitionCompaniesWarrantsMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_ReclassificationOfStockholdersEquityToWarrantLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reclassification of stockholders\u2019 equity to warrant liability,", "label": "Reclassification Of Stockholders Equity To Warrant Liability", "terseLabel": "Reclassification of stockholders\u2019 equity to warrant liability" } } }, "localname": "ReclassificationOfStockholdersEquityToWarrantLiability", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "dmtk_ReclassificationOfWarrantLiabilityDueToPrivateSPACWarrantsNotHeldByOriginalHolder": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reclassification of warrant liability due to private SPAC warrants not held by original holder.", "label": "Reclassification Of Warrant Liability Due To Private S P A C Warrants Not Held By Original Holder", "terseLabel": "Reclassification of warrant liability due to Private SPAC Warrants not held by original holder" } } }, "localname": "ReclassificationOfWarrantLiabilityDueToPrivateSPACWarrantsNotHeldByOriginalHolder", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "dmtk_RestrictedCashMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted Cash.", "label": "Restricted Cash [Member]", "terseLabel": "Restricted Cash" } } }, "localname": "RestrictedCashMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_RevisionToPriorPeriodFinancialStatementsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revision to prior period financial statements.", "label": "Revision To Prior Period Financial Statements Policy [Text Block]", "terseLabel": "Revision to Prior Period Financial Statements" } } }, "localname": "RevisionToPriorPeriodFinancialStatementsPolicyTextBlock", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "dmtk_RightOfUseAssetsRemainingLeaseTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Right of use assets remaining lease term.", "label": "Right Of Use Assets Remaining Lease Term", "terseLabel": "Remaining lease term" } } }, "localname": "RightOfUseAssetsRemainingLeaseTerm", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "dmtk_SaleOfStockClosingDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of stock closing date.", "label": "Sale Of Stock Closing Date", "terseLabel": "PIPE financing closing date" } } }, "localname": "SaleOfStockClosingDate", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "dmtk_ScheduleOfFutureMinimumRentalPaymentsForOperatingAndCapitalLeasesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of future minimum rental payments for operating and capital leases.", "label": "Schedule Of Future Minimum Rental Payments For Operating And Capital Leases Table [Text Block]", "terseLabel": "Schedule of Future Minimum Lease Payments Under Operating and Finance Leases" } } }, "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingAndCapitalLeasesTableTextBlock", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "dmtk_ScheduleOfLongTermFinanceLeaseObligationsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of long term finance lease obligations.", "label": "Schedule Of Long Term Finance Lease Obligations Table [Text Block]", "terseLabel": "Schedule of Long Term Finance Lease Obligations" } } }, "localname": "ScheduleOfLongTermFinanceLeaseObligationsTableTextBlock", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "dmtk_ScheduleOfPrepaidExpensesAndPropertyAndEquipmentTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of prepaid expenses and PP&E.", "label": "Schedule Of Prepaid Expenses And Property And Equipment Table [Text Block]", "terseLabel": "Schedule of Prepaid Expenses and PP&E" } } }, "localname": "ScheduleOfPrepaidExpensesAndPropertyAndEquipmentTableTextBlock", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsTables" ], "xbrltype": "textBlockItemType" }, "dmtk_SecuritiesPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Securities purchase agreement.", "label": "Securities Purchase Agreement [Member]", "terseLabel": "Securities Purchase Agreement" } } }, "localname": "SecuritiesPurchaseAgreementMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_SeriesAAndBConvertibleNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series A and B convertible note.", "label": "Series A And B Convertible Note [Member]", "terseLabel": "Series A and B Convertible Preferred Stock" } } }, "localname": "SeriesAAndBConvertibleNoteMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "dmtk_SeriesAConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series A convertible preferred stock.", "label": "Series A Convertible Preferred Stock [Member]", "terseLabel": "Series A Convertible Preferred Stock", "verboseLabel": "Series A convertible preferred stock" } } }, "localname": "SeriesAConvertiblePreferredStockMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" ], "xbrltype": "domainItemType" }, "dmtk_SeriesB1ConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series B-1 convertible preferred stock.", "label": "Series B1 Convertible Preferred Stock [Member]", "terseLabel": "Series B-1 Convertible Preferred Stock" } } }, "localname": "SeriesB1ConvertiblePreferredStockMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" ], "xbrltype": "domainItemType" }, "dmtk_SeriesB2ConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series B-2 convertible preferred stock.", "label": "Series B2 Convertible Preferred Stock [Member]", "terseLabel": "Series B-2 Convertible Preferred Stock" } } }, "localname": "SeriesB2ConvertiblePreferredStockMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" ], "xbrltype": "domainItemType" }, "dmtk_SeriesC2ConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series C-2 convertible preferred stock.", "label": "Series C2 Convertible Preferred Stock [Member]", "terseLabel": "Series C-2 Convertible Preferred Stock" } } }, "localname": "SeriesC2ConvertiblePreferredStockMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "dmtk_SeriesCConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series C convertible preferred stock.", "label": "Series C Convertible Preferred Stock [Member]", "terseLabel": "Series C Convertible Preferred Stock" } } }, "localname": "SeriesCConvertiblePreferredStockMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_SeriesCWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series C warrants.", "label": "Series C Warrants [Member]", "terseLabel": "Series C Warrants" } } }, "localname": "SeriesCWarrantsMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangement by share-based payment award, equity instruments other than options, vested and expected to vest, outstanding, weighted average exercise price.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price", "terseLabel": "RSUs vested and expected to vest, Weighted average grant date fair value per share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfRestrictedStockUnitsAwardTransactionsDetails" ], "xbrltype": "perShareItemType" }, "dmtk_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedButNotIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangement by share-based payment award, equity instruments other than options, vested but not issued", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Vested But Not Issued", "terseLabel": "RSUs vested, but not yet issued" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedButNotIssued", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfRestrictedStockUnitsAwardTransactionsDetails" ], "xbrltype": "sharesItemType" }, "dmtk_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedButNotIssuedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangement by share-based payment award, equity instruments other than options, vested but not issued weighted average grant date fair value", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Vested But Not Issued Weighted Average Grant Date Fair Value", "terseLabel": "RSUs vested, but not yet issued, Weighted average grant date fair value per share" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedButNotIssuedWeightedAverageGrantDateFairValue", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfRestrictedStockUnitsAwardTransactionsDetails" ], "xbrltype": "perShareItemType" }, "dmtk_SharebasedCompensationArrangementBySharebasedPaymentAwardotherThanOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangement by share-based payment award,other than options, vested and expected to vest, outstanding, number", "label": "Sharebased Compensation Arrangement By Sharebased Payment Awardother Than Options Vested And Expected To Vest Outstanding Number", "terseLabel": "RSUs vested and expected to vest" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardotherThanOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfRestrictedStockUnitsAwardTransactionsDetails" ], "xbrltype": "sharesItemType" }, "dmtk_SpecialPurposeAcquisitionCompaniesWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Special purpose acquisition companies warrants.", "label": "Special Purpose Acquisition Companies Warrants [Member]", "terseLabel": "SPAC Warrants" } } }, "localname": "SpecialPurposeAcquisitionCompaniesWarrantsMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceParentheticalDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_SpecialPurposeAcquisitionCompanyWarrantsToPurchaseCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SPAC warrants to purchase common stock.", "label": "Special Purpose Acquisition Company Warrants To Purchase Common Stock [Member]", "terseLabel": "SPAC Warrants to Purchase Common Stock" } } }, "localname": "SpecialPurposeAcquisitionCompanyWarrantsToPurchaseCommonStockMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetail" ], "xbrltype": "domainItemType" }, "dmtk_SpouseOfChiefCommercialOfficerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Spouse of chief commercial officer.", "label": "Spouse Of Chief Commercial Officer [Member]", "terseLabel": "Leana Wood" } } }, "localname": "SpouseOfChiefCommercialOfficerMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_StockIssuedDuringPeriodSharesCommonStockWarrantsExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock issued during period, shares, common stock warrants exercised.", "label": "Stock Issued During Period Shares Common Stock Warrants Exercised", "terseLabel": "Issuance of common stock from warrant exercises, Shares" } } }, "localname": "StockIssuedDuringPeriodSharesCommonStockWarrantsExercised", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "dmtk_StockIssuedDuringPeriodSharesStockOptionsExercisedAndRSURelease": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock issued during period shares stock options exercised and RSU release.", "label": "Stock Issued During Period Shares Stock Options Exercised And R S U Release", "terseLabel": "Issuance of common stock from option exercises and RSU releases, Shares" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercisedAndRSURelease", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "dmtk_StockIssuedDuringPeriodValueCommonStockWarrantsExercised": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock issued during period value common stock warrants exercised.", "label": "Stock Issued During Period Value Common Stock Warrants Exercised", "terseLabel": "Issuance of common stock from warrant exercises" } } }, "localname": "StockIssuedDuringPeriodValueCommonStockWarrantsExercised", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "dmtk_StockIssuedDuringPeriodValueStockOptionsExercisedAndRSURelease": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock issued during period value stock options exercised and RSU release.", "label": "Stock Issued During Period Value Stock Options Exercised And R S U Release", "terseLabel": "Issuance of common stock from option exercises and RSU releases" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercisedAndRSURelease", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "dmtk_StockOptionsAndRestrictedStockUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock options and restricted stock units.", "label": "Stock Options And Restricted Stock Units [Member]", "terseLabel": "Stock Options and Restricted Stock Units" } } }, "localname": "StockOptionsAndRestrictedStockUnitsMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_StockPurchasedByUnderwritersPursuantToOptionGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock purchased by underwriters pursuant to option granted.", "label": "Stock Purchased By Underwriters Pursuant To Option Granted", "terseLabel": "Shares purchased by underwriters" } } }, "localname": "StockPurchasedByUnderwritersPursuantToOptionGranted", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "dmtk_TenantImprovementAllowance": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Tenant improvement allowance.", "label": "Tenant Improvement Allowance", "terseLabel": "Tenant improvement allowance" } } }, "localname": "TenantImprovementAllowance", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_TenantImprovementAllowancePerRentableSquareFoot": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tenant improvement allowance per rentable square foot.", "label": "Tenant Improvement Allowance Per Rentable Square Foot", "terseLabel": "Tenant improvement allowance per rentable square foot" } } }, "localname": "TenantImprovementAllowancePerRentableSquareFoot", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "perUnitItemType" }, "dmtk_TheCompanyAndSummaryOfItsSignificantAccountingPoliciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The company and summary of its significant accounting policies.", "label": "The Company And Summary Of Its Significant Accounting Policies [Line Items]", "terseLabel": "The Company and Summary of its Significant Accounting Policies [Line Items]" } } }, "localname": "TheCompanyAndSummaryOfItsSignificantAccountingPoliciesLineItems", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails1" ], "xbrltype": "stringItemType" }, "dmtk_TheCompanyAndSummaryOfItsSignificantAccountingPoliciesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The company and summary of its significant accounting policies.", "label": "The Company And Summary Of Its Significant Accounting Policies [Table]", "terseLabel": "The Company And Summary Of Its Significant Accounting Policies [Table]" } } }, "localname": "TheCompanyAndSummaryOfItsSignificantAccountingPoliciesTable", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails1" ], "xbrltype": "stringItemType" }, "dmtk_TwoThousandAndTwentyPIPEFinancingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2020 PIPE Financing.", "label": "Two Thousand And Twenty P I P E Financing [Member]", "terseLabel": "2020 PIPE Financing" } } }, "localname": "TwoThousandAndTwentyPIPEFinancingMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_TwoThousandEighteenConvertibleBridgeNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand eighteen convertible bridge notes.", "label": "Two Thousand Eighteen Convertible Bridge Notes [Member]", "terseLabel": "2018 Convertible Bridge Notes" } } }, "localname": "TwoThousandEighteenConvertibleBridgeNotesMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_TwoThousandNineteenConvertibleBridgeNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand nineteen convertible bridge notes.", "label": "Two Thousand Nineteen Convertible Bridge Notes [Member]", "terseLabel": "2019 Convertible Bridge Notes" } } }, "localname": "TwoThousandNineteenConvertibleBridgeNotesMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_TwoThousandTenStockPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand ten stock plan.", "label": "Two Thousand Ten Stock Plan [Member]", "terseLabel": "2010 Stock Plan" } } }, "localname": "TwoThousandTenStockPlanMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dmtk_TwoThousandTwentyEmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand twenty employee stock purchase plan.", "label": "Two Thousand Twenty Employee Stock Purchase Plan [Member]", "terseLabel": "2020 Employee Stock Purchase Plan" } } }, "localname": "TwoThousandTwentyEmployeeStockPurchasePlanMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAssumptionsUsedToDetermineFairValueOfEachOptionOnDateOfGrantIssuedDetails" ], "xbrltype": "domainItemType" }, "dmtk_TwoThousandTwentyEquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand twenty equity incentive plan.", "label": "Two Thousand Twenty Equity Incentive Plan [Member]", "terseLabel": "2020 Equity Incentive Plan" } } }, "localname": "TwoThousandTwentyEquityIncentivePlanMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAssumptionsUsedToDetermineFairValueOfEachOptionOnDateOfGrantIssuedDetails" ], "xbrltype": "domainItemType" }, "dmtk_UncertainTaxPositionsPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Uncertain tax positions percentage.", "label": "Uncertain Tax Positions Percentage", "terseLabel": "Uncertain tax positions percentage" } } }, "localname": "UncertainTaxPositionsPercentage", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "dmtk_UnderwritersGrantPeriodOption": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Underwriters grant period option.", "label": "Underwriters Grant Period Option", "terseLabel": "Number of days granted to underwriters option to purchase" } } }, "localname": "UnderwritersGrantPeriodOption", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "dmtk_UnpaidDeferredIssuanceCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Unpaid deferred issuance costs.", "label": "Unpaid Deferred Issuance Costs", "terseLabel": "Unpaid deferred issuance costs" } } }, "localname": "UnpaidDeferredIssuanceCosts", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "dmtk_WarrantLiabilityFairValueDisclosure": { "auth_ref": [], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": { "order": 10010.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Warrant liability fair value disclosure.", "label": "Warrant Liability Fair Value Disclosure", "terseLabel": "Warrant liability" } } }, "localname": "WarrantLiabilityFairValueDisclosure", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_WarrantLiabilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrant liability.", "label": "Warrant Liability [Member]", "terseLabel": "Warrant Liability" } } }, "localname": "WarrantLiabilityMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfChangesInFairValueOfLevel3LiabilitiesDetails" ], "xbrltype": "domainItemType" }, "dmtk_WarrantLiabilityNonCurrent": { "auth_ref": [], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfImpactOfConsolidatedBalanceSheetsFromAdjustmentDetails": { "order": 10010.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Warrant liability non current.", "label": "Warrant Liability Non Current", "terseLabel": "Warrant liability" } } }, "localname": "WarrantLiabilityNonCurrent", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfImpactOfConsolidatedBalanceSheetsFromAdjustmentDetails" ], "xbrltype": "monetaryItemType" }, "dmtk_WarrantLiabilityPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrant liability.", "label": "Warrant Liability Policy [Text Block]", "terseLabel": "Warrant Liability" } } }, "localname": "WarrantLiabilityPolicyTextBlock", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "dmtk_WarrantsToPurchaseCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants to purchase common stock.", "label": "Warrants To Purchase Common Stock [Member]", "terseLabel": "Warrants to Purchase Common Stock" } } }, "localname": "WarrantsToPurchaseCommonStockMember", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetail" ], "xbrltype": "domainItemType" }, "dmtk_WarrantsVestingPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants vesting period.", "label": "Warrants Vesting Period", "terseLabel": "Warrants vesting period" } } }, "localname": "WarrantsVestingPeriod", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "dmtk_WeightedAveragePurchasePricePerShareInOffering": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average purchase price per share in offering.", "label": "Weighted Average Purchase Price Per Share In Offering", "terseLabel": "Issuance price per share" } } }, "localname": "WeightedAveragePurchasePricePerShareInOffering", "nsuri": "http://dermtech.com/20211231", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" ], "xbrltype": "perShareItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r62", "r64", "r114", "r115", "r247", "r287" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": { "auth_ref": [ "r0", "r121", "r127", "r134", "r205", "r383", "r384", "r385", "r410", "r411", "r438", "r440", "r441", "r442", "r618" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect Period Of Adoption Adjustment [Member]", "terseLabel": "Cumulative Effect Adjustment of Accounting Method Change" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAxis": { "auth_ref": [ "r0", "r121", "r127", "r134", "r205", "r383", "r384", "r385", "r410", "r411", "r438", "r440", "r441", "r442", "r618" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect Period Of Adoption [Axis]", "terseLabel": "Cumulative Effect, Period of Adoption" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionDomain": { "auth_ref": [ "r0", "r121", "r127", "r134", "r205", "r383", "r384", "r385", "r410", "r411", "r438", "r440", "r441", "r442", "r618" ], "lang": { "en-us": { "role": { "label": "Cumulative Effect Period Of Adoption [Domain]", "terseLabel": "Cumulative Effect, Period of Adoption" } } }, "localname": "CumulativeEffectPeriodOfAdoptionDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r246", "r286", "r347", "r349", "r508", "r509", "r510", "r511", "r512", "r513", "r532", "r574", "r576", "r598", "r599" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails1", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAssumptionsUsedToCalculateFairValueOfWarrantLiabilityUsingBlackScholesMertonValuationModelDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAssumptionsUsedToDetermineFairValueOfEachOptionOnDateOfGrantIssuedDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfPercentagesOfTotalRevenueOrAccountsReceivableForThirdPartyPayersAndPharmaceuticalCustomersParentheticalDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r246", "r286", "r347", "r349", "r508", "r509", "r510", "r511", "r512", "r513", "r532", "r574", "r576", "r598", "r599" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails1", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAssumptionsUsedToCalculateFairValueOfWarrantLiabilityUsingBlackScholesMertonValuationModelDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAssumptionsUsedToDetermineFairValueOfEachOptionOnDateOfGrantIssuedDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfPercentagesOfTotalRevenueOrAccountsReceivableForThirdPartyPayersAndPharmaceuticalCustomersParentheticalDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r181", "r316", "r317", "r534", "r573", "r575" ], "lang": { "en-us": { "role": { "label": "Product Or Service [Axis]", "terseLabel": "Product and Service" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesScheduleOfRevenuesDisaggregatedByRevenueSourceDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfPercentagesOfTotalRevenueOrAccountsReceivableForThirdPartyPayersAndPharmaceuticalCustomersDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfPercentagesOfTotalRevenueOrAccountsReceivableForThirdPartyPayersAndPharmaceuticalCustomersParentheticalDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r181", "r316", "r317", "r534", "r573", "r575" ], "lang": { "en-us": { "role": { "label": "Products And Services [Domain]", "terseLabel": "Product and Service" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesScheduleOfRevenuesDisaggregatedByRevenueSourceDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfPercentagesOfTotalRevenueOrAccountsReceivableForThirdPartyPayersAndPharmaceuticalCustomersDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfPercentagesOfTotalRevenueOrAccountsReceivableForThirdPartyPayersAndPharmaceuticalCustomersParentheticalDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r246", "r286", "r326", "r347", "r349", "r508", "r509", "r510", "r511", "r512", "r513", "r532", "r574", "r576", "r598", "r599" ], "lang": { "en-us": { "role": { "label": "Range [Axis]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails1", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAssumptionsUsedToCalculateFairValueOfWarrantLiabilityUsingBlackScholesMertonValuationModelDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAssumptionsUsedToDetermineFairValueOfEachOptionOnDateOfGrantIssuedDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfPercentagesOfTotalRevenueOrAccountsReceivableForThirdPartyPayersAndPharmaceuticalCustomersParentheticalDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r246", "r286", "r326", "r347", "r349", "r508", "r509", "r510", "r511", "r512", "r513", "r532", "r574", "r576", "r598", "r599" ], "lang": { "en-us": { "role": { "label": "Range [Member]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails1", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAssumptionsUsedToCalculateFairValueOfWarrantLiabilityUsingBlackScholesMertonValuationModelDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAssumptionsUsedToDetermineFairValueOfEachOptionOnDateOfGrantIssuedDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfPercentagesOfTotalRevenueOrAccountsReceivableForThirdPartyPayersAndPharmaceuticalCustomersParentheticalDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r63", "r64", "r114", "r115", "r247", "r287" ], "lang": { "en-us": { "role": { "label": "Repurchase Agreement Counterparty Name [Domain]", "terseLabel": "Counterparty Name" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_RestatementAxis": { "auth_ref": [ "r1", "r118", "r119", "r120", "r122", "r123", "r124", "r125", "r126", "r127", "r129", "r130", "r131", "r132", "r133", "r134", "r144", "r206", "r207", "r386", "r411", "r439", "r441", "r442", "r443", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r619", "r620" ], "lang": { "en-us": { "role": { "label": "Restatement [Axis]", "terseLabel": "Revision of Prior Period" } } }, "localname": "RestatementAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfImpactOfConsolidatedBalanceSheetsFromAdjustmentDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfImpactOfConsolidatedStatementsOfOperationsFromAdjustmentDetails" ], "xbrltype": "stringItemType" }, "srt_RestatementDomain": { "auth_ref": [ "r1", "r118", "r119", "r120", "r122", "r123", "r124", "r125", "r126", "r127", "r129", "r130", "r131", "r132", "r133", "r134", "r144", "r206", "r207", "r386", "r411", "r439", "r441", "r442", "r443", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r619", "r620" ], "lang": { "en-us": { "role": { "label": "Restatement [Domain]", "terseLabel": "Revision of Prior Period" } } }, "localname": "RestatementDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfImpactOfConsolidatedBalanceSheetsFromAdjustmentDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfImpactOfConsolidatedStatementsOfOperationsFromAdjustmentDetails" ], "xbrltype": "domainItemType" }, "srt_RevisionOfPriorPeriodErrorCorrectionAdjustmentMember": { "auth_ref": [ "r124", "r125", "r126", "r129", "r130", "r132", "r133" ], "lang": { "en-us": { "role": { "label": "Revision Of Prior Period Error Correction Adjustment [Member]", "terseLabel": "Adjustments" } } }, "localname": "RevisionOfPriorPeriodErrorCorrectionAdjustmentMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfImpactOfConsolidatedBalanceSheetsFromAdjustmentDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfImpactOfConsolidatedStatementsOfOperationsFromAdjustmentDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioPreviouslyReportedMember": { "auth_ref": [ "r1", "r118", "r120", "r122", "r123", "r124", "r125", "r126", "r127", "r129", "r130", "r132", "r133", "r144", "r206", "r207", "r386", "r411", "r439", "r441", "r442", "r443", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r619", "r620" ], "lang": { "en-us": { "role": { "label": "Scenario Previously Reported [Member]", "terseLabel": "As Previously Reported" } } }, "localname": "ScenarioPreviouslyReportedMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfImpactOfConsolidatedBalanceSheetsFromAdjustmentDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfImpactOfConsolidatedStatementsOfOperationsFromAdjustmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r45", "r499" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10120.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableGrossCurrent": { "auth_ref": [ "r184", "r185" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable Gross Current", "verboseLabel": "Accounts receivable gross" } } }, "localname": "AccountsReceivableGrossCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [ "r595" ], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]", "terseLabel": "Accounts Receivable" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfPercentagesOfTotalRevenueOrAccountsReceivableForThirdPartyPayersAndPharmaceuticalCustomersDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfPercentagesOfTotalRevenueOrAccountsReceivableForThirdPartyPayersAndPharmaceuticalCustomersParentheticalDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r6", "r30", "r184", "r185" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10250.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable Net Current", "terseLabel": "Accounts receivable", "verboseLabel": "Accounts receivable" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "auth_ref": [ "r98" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10320.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Accretion Amortization Of Discounts And Premiums Investments", "negatedLabel": "Amortization (Accretion) of discount (premium) on marketable securities" } } }, "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r48" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfAccruedCompensationAndAccruedLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10140.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities Current", "terseLabel": "Accrued liabilities", "totalLabel": "Total accrued liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfAccruedCompensationAndAccruedLiabilitiesDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accrued Liabilities Current [Abstract]", "terseLabel": "Accrued liabilities:" } } }, "localname": "AccruedLiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfAccruedCompensationAndAccruedLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccruedVacationCurrent": { "auth_ref": [ "r14", "r48", "r325" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfAccruedCompensationAndAccruedLiabilitiesDetails": { "order": 10030.0, "parentTag": "us-gaap_EmployeeRelatedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Vacation Current", "terseLabel": "Accrued paid time off" } } }, "localname": "AccruedVacationCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfAccruedCompensationAndAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r43", "r223" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndPPEDetails": { "order": 10020.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation Depletion And Amortization Property Plant And Equipment", "negatedLabel": "Less accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndPPEDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": { "auth_ref": [ "r66", "r67", "r68", "r71", "r78", "r79", "r80" ], "lang": { "en-us": { "role": { "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.", "label": "Accumulated Net Unrealized Investment Gain Loss [Member]", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r33", "r69", "r70", "r71", "r566", "r582", "r586" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10050.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income Loss Net Of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r31" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10040.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid In Capital Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfImpactOfConsolidatedBalanceSheetsFromAdjustmentDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r118", "r119", "r120", "r383", "r384", "r385", "r441" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid In Capital [Member]", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for restricted stock unit under share-based payment arrangement.", "label": "Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition", "terseLabel": "Restricted stock unit release" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r351", "r353", "r389", "r390" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value", "terseLabel": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": { "auth_ref": [ "r300", "r308" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.", "label": "Adjustments To Additional Paid In Capital Stock Issued Issuance Costs", "terseLabel": "Issuance costs" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r353", "r379", "r388" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Allocated Share Based Compensation Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "auth_ref": [ "r97", "r266", "r274", "r275", "r467" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10290.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.", "label": "Amortization Of Financing Costs And Discounts", "terseLabel": "Amortization of debt discount and issuance costs" } } }, "localname": "AmortizationOfFinancingCostsAndDiscounts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r142" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount", "terseLabel": "Anti-dilutive equity instruments excluded from diluted net loss per common share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r142" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r142" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities Name [Domain]", "terseLabel": "Antidilutive Securities, Name" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Arrangements And Nonarrangement Transactions [Member]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r112", "r164", "r173", "r179", "r204", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r423", "r427", "r457", "r497", "r499", "r548", "r565" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r9", "r11", "r61", "r112", "r204", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r423", "r427", "r457", "r497", "r499" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10180.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r444" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets Fair Value Disclosure", "totalLabel": "Total assets measured at fair value on a recurring basis" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets Fair Value Disclosure [Abstract]", "terseLabel": "Assets:" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r195" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfShortTermMarketableSecuritiesDetails": { "order": 10010.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax", "terseLabel": "Gross Unrealized Gain" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfShortTermMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r196" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfShortTermMarketableSecuritiesDetails": { "order": 10020.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax", "negatedLabel": "Gross Unrealized Loss" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfShortTermMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r193", "r213" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfShortTermMarketableSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available For Sale Debt Securities Amortized Cost Basis", "totalLabel": "Amortized Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfShortTermMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r191", "r194", "r213", "r553" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfShortTermMarketableSecuritiesDetails": { "order": 10030.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 }, "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": { "order": 10040.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Available For Sale Securities Debt Securities", "terseLabel": "Marketable securities, available for sale" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfShortTermMarketableSecuritiesDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r354", "r381" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetail", "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfRestrictedStockUnitsAwardTransactionsDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfStockOptionsTransactionsDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r432", "r434" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis Of Accounting Policy Policy [Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r346", "r348" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingencieAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r346", "r348", "r418", "r419" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingencieAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r102", "r103", "r104" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred But Not Yet Paid", "terseLabel": "Purchases of property and equipment recorded in accounts payable" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r4", "r40", "r99" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10230.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash And Cash Equivalents At Carrying Value", "periodEndLabel": "Cash and cash equivalents, end of period", "periodStartLabel": "Cash and cash equivalents, beginning of period", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "auth_ref": [ "r17", "r100", "r547" ], "lang": { "en-us": { "role": { "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.", "label": "Cash And Cash Equivalents Restricted Cash And Cash Equivalents Policy", "terseLabel": "Cash, Cash Equivalents and Restricted Cash" } } }, "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r93", "r99", "r105" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations", "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r93", "r458" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect", "totalLabel": "Net increase in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsAtCarryingValue": { "auth_ref": [ "r40" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": { "order": 10020.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash Equivalents At Carrying Value", "terseLabel": "Cash equivalents" } } }, "localname": "CashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFDICInsuredAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.", "label": "Cash F D I C Insured Amount", "terseLabel": "Insured amount by FDIC" } } }, "localname": "CashFDICInsuredAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashUninsuredAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.", "label": "Cash Uninsured Amount", "terseLabel": "Cash held in excess of FDIC limit" } } }, "localname": "CashUninsuredAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r109", "r112", "r135", "r136", "r137", "r139", "r141", "r146", "r147", "r148", "r204", "r231", "r235", "r236", "r237", "r240", "r241", "r284", "r285", "r289", "r293", "r457", "r609" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class Of Stock [Domain]", "terseLabel": "Class of Stock" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class Of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetail", "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceParentheticalDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r311", "r352" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class Of Warrant Or Right [Axis]", "terseLabel": "Class of Warrant or Right" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceParentheticalDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Class Of Warrant Or Right [Domain]", "terseLabel": "Class of Warrant or Right" } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceParentheticalDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r301" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1", "terseLabel": "Exercise price of warrant" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.", "label": "Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right", "terseLabel": "Number of shares issued for each warrant" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceParentheticalDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r301" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights", "terseLabel": "Total number exercised of public warrants" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Class Of Warrant Or Right Outstanding", "terseLabel": "Warrants outstanding" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments And Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsDisclosureTextBlock": { "auth_ref": [ "r227" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.", "label": "Commitments Disclosure [Text Block]", "terseLabel": "Leases, Commitments and Contingencies" } } }, "localname": "CommitmentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r55" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock Capital Shares Reserved For Future Issuance", "terseLabel": "Common stock reserved for future issuance", "verboseLabel": "Common stock available for issuance" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r118", "r119", "r441" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock", "verboseLabel": "Common stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceParentheticalDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r29" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock Par Or Stated Value Per Share", "terseLabel": "Common stock, par value", "verboseLabel": "Common stock, par value per share" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r29" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r29" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock Shares Issued", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r29", "r300" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock Shares Outstanding", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r29", "r499" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10030.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock Value", "terseLabel": "Common stock, $0.0001 par value per share; 50,000,000 shares authorized as of December 31, 2021 and 2020; 29,772,922 and 20,740,413 shares issued and outstanding at December 31, 2021 and 2020, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Compensation And Retirement Disclosure [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Components Of Deferred Tax Assets And Liabilities [Abstract]" } } }, "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r73", "r75", "r76", "r82", "r556", "r572" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income Net Of Tax", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Comprehensive Income Policy Policy [Text Block]", "terseLabel": "Comprehensive Loss" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r155", "r156", "r183", "r455", "r456", "r595" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfPercentagesOfTotalRevenueOrAccountsReceivableForThirdPartyPayersAndPharmaceuticalCustomersDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfPercentagesOfTotalRevenueOrAccountsReceivableForThirdPartyPayersAndPharmaceuticalCustomersParentheticalDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r155", "r156", "r183", "r455", "r456", "r588", "r595" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk By Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfPercentagesOfTotalRevenueOrAccountsReceivableForThirdPartyPayersAndPharmaceuticalCustomersDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfPercentagesOfTotalRevenueOrAccountsReceivableForThirdPartyPayersAndPharmaceuticalCustomersParentheticalDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r155", "r156", "r183", "r455", "r456", "r588", "r595" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk By Type [Axis]", "terseLabel": "Concentration Risk Type" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfPercentagesOfTotalRevenueOrAccountsReceivableForThirdPartyPayersAndPharmaceuticalCustomersDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfPercentagesOfTotalRevenueOrAccountsReceivableForThirdPartyPayersAndPharmaceuticalCustomersParentheticalDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r151", "r562" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk Credit Risk", "terseLabel": "Concentration of Credit Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r155", "r156", "r183", "r455", "r456" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk Percentage1", "terseLabel": "Concentration risk, percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfPercentagesOfTotalRevenueOrAccountsReceivableForThirdPartyPayersAndPharmaceuticalCustomersDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfPercentagesOfTotalRevenueOrAccountsReceivableForThirdPartyPayersAndPharmaceuticalCustomersParentheticalDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r155", "r156", "r183", "r455", "r456", "r595" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfPercentagesOfTotalRevenueOrAccountsReceivableForThirdPartyPayersAndPharmaceuticalCustomersDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfPercentagesOfTotalRevenueOrAccountsReceivableForThirdPartyPayersAndPharmaceuticalCustomersParentheticalDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertibleDebtCurrent": { "auth_ref": [ "r21" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Convertible Debt Current", "verboseLabel": "Liability balance" } } }, "localname": "ConvertibleDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtMember": { "auth_ref": [ "r242", "r243", "r244", "r246", "r256", "r257", "r258", "r262", "r263", "r264", "r265", "r266", "r272", "r273", "r274", "r275" ], "lang": { "en-us": { "role": { "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.", "label": "Convertible Debt [Member]", "terseLabel": "Convertible notes" } } }, "localname": "ConvertibleDebtMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r327", "r342", "r587" ], "lang": { "en-us": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate Debt Securities" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfShortTermMarketableSecuritiesDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r84", "r112", "r204", "r231", "r232", "r233", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r457" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "order": 10130.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost Of Revenue", "terseLabel": "Cost of revenues" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesPolicyTextBlock": { "auth_ref": [ "r324" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.", "label": "Cost Of Sales Policy [Text Block]", "terseLabel": "Freight and Shipping Costs" } } }, "localname": "CostOfSalesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r154", "r183" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfPercentagesOfTotalRevenueOrAccountsReceivableForThirdPartyPayersAndPharmaceuticalCustomersDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfPercentagesOfTotalRevenueOrAccountsReceivableForThirdPartyPayersAndPharmaceuticalCustomersParentheticalDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "auth_ref": [ "r102", "r104" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.", "label": "Debt Conversion Converted Instrument Shares Issued1", "verboseLabel": "Convertible debt converted in to common shares" } } }, "localname": "DebtConversionConvertedInstrumentSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r108", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r260", "r267", "r268", "r270", "r278" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Debt" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureDebt" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r21", "r22", "r23", "r111", "r116", "r243", "r244", "r245", "r246", "r247", "r248", "r250", "r256", "r257", "r258", "r259", "r261", "r262", "r263", "r264", "r265", "r266", "r272", "r273", "r274", "r275", "r468", "r549", "r551", "r564" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "auth_ref": [ "r245", "r271" ], "lang": { "en-us": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "Debt Instrument Convertible Conversion Price1", "terseLabel": "Convertible notes conversion price" } } }, "localname": "DebtInstrumentConvertibleConversionPrice1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentConvertibleConversionRatio1": { "auth_ref": [ "r52", "r245", "r301", "r304", "r306" ], "lang": { "en-us": { "role": { "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.", "label": "Debt Instrument Convertible Conversion Ratio1", "terseLabel": "Convertible notes conversion ratio" } } }, "localname": "DebtInstrumentConvertibleConversionRatio1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "pureItemType" }, "us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature": { "auth_ref": [ "r52", "r301", "r305", "r306" ], "lang": { "en-us": { "role": { "documentation": "Description of conversion terms for debt instrument.", "label": "Debt Instrument Convertible Terms Of Conversion Feature", "terseLabel": "Debt conversion feature" } } }, "localname": "DebtInstrumentConvertibleTermsOfConversionFeature", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r243", "r272", "r273", "r466", "r468", "r469" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument Face Amount", "terseLabel": "Convertible note, principal amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateIncreaseDecrease": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Incremental percentage increase (decrease) in the stated rate on a debt instrument.", "label": "Debt Instrument Interest Rate Increase Decrease", "terseLabel": "Increase in interest rate if bridge notes not paid or converted" } } }, "localname": "DebtInstrumentInterestRateIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r50", "r244" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument Interest Rate Stated Percentage", "terseLabel": "Debt instrument, interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentMaturityDate": { "auth_ref": [ "r51", "r246", "r449" ], "lang": { "en-us": { "role": { "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.", "label": "Debt Instrument Maturity Date", "terseLabel": "Debt maturity date" } } }, "localname": "DebtInstrumentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentMaturityDateDescription": { "auth_ref": [ "r51" ], "lang": { "en-us": { "role": { "documentation": "Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.", "label": "Debt Instrument Maturity Date Description", "terseLabel": "Maturity date, description" } } }, "localname": "DebtInstrumentMaturityDateDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r53", "r111", "r116", "r243", "r244", "r245", "r246", "r247", "r248", "r250", "r256", "r257", "r258", "r259", "r261", "r262", "r263", "r264", "r265", "r266", "r272", "r273", "r274", "r275", "r468" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument Name [Domain]", "terseLabel": "Debt Instrument, Name" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r53", "r111", "r116", "r243", "r244", "r245", "r246", "r247", "r248", "r250", "r256", "r257", "r258", "r259", "r261", "r262", "r263", "r264", "r265", "r266", "r269", "r272", "r273", "r274", "r275", "r301", "r305", "r306", "r307", "r465", "r466", "r468", "r469", "r561" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Debt Instrument [Table]", "terseLabel": "Debt Instrument [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r256", "r465", "r469" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Debt Instrument Unamortized Discount", "terseLabel": "Debt discount" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "auth_ref": [ "r199" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities Available For Sale Table [Text Block]", "terseLabel": "Schedule of Short-Term Marketable Securities" } } }, "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredCostsCurrent": { "auth_ref": [ "r59" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndPPEDetails": { "order": 10100.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer.", "label": "Deferred Costs Current", "terseLabel": "Deferred issuance costs" } } }, "localname": "DeferredCostsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndPPEDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilities": { "auth_ref": [ "r24", "r25", "r399", "r550", "r563" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesFromFederalAndStateIncomeTaxesDetails": { "order": 10040.0, "parentTag": "dmtk_DeferredTaxAssetsLiabilitiesBeforeValuationAllowance", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.", "label": "Deferred Income Tax Liabilities", "negatedTotalLabel": "Total deferred tax liabilities" } } }, "localname": "DeferredIncomeTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesFromFederalAndStateIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueCurrent": { "auth_ref": [ "r37" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10150.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.", "label": "Deferred Revenue Current", "verboseLabel": "Short-term deferred revenue" } } }, "localname": "DeferredRevenueCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueNoncurrent": { "auth_ref": [ "r37" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10090.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Deferred Revenue Noncurrent", "terseLabel": "Long-term deferred revenue" } } }, "localname": "DeferredRevenueNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsDeferredIncome": { "auth_ref": [ "r407", "r408" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesFromFederalAndStateIncomeTaxesDetails": { "order": 10130.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.", "label": "Deferred Tax Assets Deferred Income", "terseLabel": "Deferred revenue" } } }, "localname": "DeferredTaxAssetsDeferredIncome", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesFromFederalAndStateIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r400" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesFromFederalAndStateIncomeTaxesDetails": { "order": 10030.0, "parentTag": "dmtk_DeferredTaxAssetsLiabilitiesBeforeValuationAllowance", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets Gross", "totalLabel": "Total deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesFromFederalAndStateIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": { "auth_ref": [ "r407", "r408" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesFromFederalAndStateIncomeTaxesDetails": { "order": 10080.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.", "label": "Deferred Tax Assets In Process Research And Development", "terseLabel": "Research and development credits" } } }, "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesFromFederalAndStateIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r402" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesFromFederalAndStateIncomeTaxesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "Deferred Tax Assets Liabilities Net", "totalLabel": "Net deferred tax assets" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesFromFederalAndStateIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets Net Of Valuation Allowance [Abstract]", "terseLabel": "Deferred tax assets:" } } }, "localname": "DeferredTaxAssetsNetOfValuationAllowanceAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesFromFederalAndStateIncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r407", "r408" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesFromFederalAndStateIncomeTaxesDetails": { "order": 10070.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Deferred Tax Assets Operating Loss Carryforwards", "terseLabel": "Net operating loss" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesFromFederalAndStateIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOther": { "auth_ref": [ "r407", "r408" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesFromFederalAndStateIncomeTaxesDetails": { "order": 10110.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.", "label": "Deferred Tax Assets Other", "terseLabel": "Accruals and other" } } }, "localname": "DeferredTaxAssetsOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesFromFederalAndStateIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "auth_ref": [ "r407", "r408" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesFromFederalAndStateIncomeTaxesDetails": { "order": 10100.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.", "label": "Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost", "terseLabel": "Stock based compensation" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesFromFederalAndStateIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r401" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesFromFederalAndStateIncomeTaxesDetails": { "order": 10020.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets Valuation Allowance", "negatedLabel": "Less: valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesFromFederalAndStateIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Tax Liabilities Net [Abstract]", "terseLabel": "Deferred tax liabilities:" } } }, "localname": "DeferredTaxLiabilitiesNetAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesFromFederalAndStateIncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DepositsMoneyMarketDeposits": { "auth_ref": [ "r554" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deposits in accounts that offer many of the same services as checking accounts although transactions may be somewhat more limited, share some of the characteristics of a money market fund and are insured by the Federal government, also known as money market accounts.", "label": "Deposits Money Market Deposits", "terseLabel": "Sweep account" } } }, "localname": "DepositsMoneyMarketDeposits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r97", "r221" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10250.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation", "verboseLabel": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r97", "r221" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation And Amortization", "terseLabel": "Accumulated amortization", "verboseLabel": "Accumulated amortization" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLossOnDerivative": { "auth_ref": [ "r433" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10280.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "order": 10060.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in the fair value of derivatives recognized in the income statement.", "label": "Derivative Loss On Derivative", "negatedLabel": "Change in fair value of derivative liability", "terseLabel": "Change in fair value of derivative liability" } } }, "localname": "DerivativeLossOnDerivative", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation Of Revenue [Line Items]", "terseLabel": "Disaggregation Of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesScheduleOfRevenuesDisaggregatedByRevenueSourceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation Of Revenue [Table]", "terseLabel": "Disaggregation Of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesScheduleOfRevenuesDisaggregatedByRevenueSourceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r316" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation Of Revenue Table [Text Block]", "terseLabel": "Schedule of Revenues Disaggregated by Revenue Source" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Country [Member]", "terseLabel": "Domestic tax authority" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r140" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share Basic And Diluted", "terseLabel": "Net loss per share of common stock outstanding, basic and diluted" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfImpactOfConsolidatedStatementsOfOperationsFromAdjustmentDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r142", "r143" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share Policy [Text Block]", "terseLabel": "Net Loss Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r394" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxRateDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Continuing Operations", "totalLabel": "Income tax expense" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Continuing Operations Tax Rate Reconciliation [Abstract]" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r113", "r394", "r413" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxRateDetails": { "order": 10010.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate", "terseLabel": "Income tax at statutory rate", "verboseLabel": "Federal statutory rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r394", "r413" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxRateDetails": { "order": 10060.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.", "label": "Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance", "terseLabel": "Valuation allowance (decrease) increase" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": { "auth_ref": [], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxRateDetails": { "order": 10050.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.", "label": "Effective Income Tax Rate Reconciliation Other Reconciling Items Percent", "terseLabel": "Other" } } }, "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r394", "r413" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxRateDetails": { "order": 10020.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation State And Local Income Taxes", "terseLabel": "State tax, net of federal tax benefit" } } }, "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": { "auth_ref": [ "r394", "r413" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxRateDetails": { "order": 10040.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.", "label": "Effective Income Tax Rate Reconciliation Tax Credits", "terseLabel": "Tax credits" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmbeddedDerivativeLossOnEmbeddedDerivative": { "auth_ref": [ "r436" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Decrease in the fair value of the embedded derivative or group of embedded derivatives included in earnings in the period.", "label": "Embedded Derivative Loss On Embedded Derivative", "terseLabel": "Loss on change in fair value of derivative liability" } } }, "localname": "EmbeddedDerivativeLossOnEmbeddedDerivative", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r48" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfAccruedCompensationAndAccruedLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10130.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee Related Liabilities Current", "terseLabel": "Accrued compensation", "totalLabel": "Total accrued compensation" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfAccruedCompensationAndAccruedLiabilitiesDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Employee Related Liabilities Current [Abstract]", "terseLabel": "Accrued compensation:" } } }, "localname": "EmployeeRelatedLiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfAccruedCompensationAndAccruedLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r380" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized", "terseLabel": "Compensation cost related to non-vested awards not yet recognized" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r380" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1", "terseLabel": "Weighted average term expected to be recognized" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.", "label": "Employee Stock [Member]", "terseLabel": "Stock Option [Member]" } } }, "localname": "EmployeeStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfStockOptionsTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r378" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Employee Stock Option [Member]", "terseLabel": "Stock Options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetail", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r78", "r79", "r80", "r118", "r119", "r120", "r123", "r130", "r133", "r145", "r205", "r300", "r308", "r383", "r384", "r385", "r410", "r411", "r441", "r459", "r460", "r461", "r462", "r463", "r464", "r577", "r578", "r579", "r620" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceParentheticalDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "auth_ref": [ "r203" ], "lang": { "en-us": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.", "label": "Equity Method Investment Ownership Percentage", "terseLabel": "Ownership interest" } } }, "localname": "EquityMethodInvestmentOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Error Corrections And Prior Period Adjustments Restatement [Line Items]", "terseLabel": "Error Corrections And Prior Period Adjustments Restatement [Line Items]" } } }, "localname": "ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfImpactOfConsolidatedBalanceSheetsFromAdjustmentDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfImpactOfConsolidatedStatementsOfOperationsFromAdjustmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAdjustmentOfWarrants": { "auth_ref": [ "r97", "r279" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10260.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "order": 10040.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "Fair Value Adjustment Of Warrants", "negatedLabel": "Change in fair value of warrant liability", "terseLabel": "Change in fair value of warrant liability" } } }, "localname": "FairValueAdjustmentOfWarrants", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfImpactOfConsolidatedStatementsOfOperationsFromAdjustmentDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Abstract]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r444", "r445", "r446", "r453" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAssumptionsUsedToCalculateFairValueOfWarrantLiabilityUsingBlackScholesMertonValuationModelDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "auth_ref": [ "r447" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAssumptionsUsedToCalculateFairValueOfWarrantLiabilityUsingBlackScholesMertonValuationModelDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "auth_ref": [ "r447" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques Table [Text Block]", "terseLabel": "Summary of Assumptions Used to Calculate Fair Value of Warrant Liability Using Black-Scholes-Merton Valuation Model" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r258", "r272", "r273", "r327", "r329", "r330", "r331", "r332", "r333", "r334", "r342", "r445", "r505", "r506", "r507" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value By Fair Value Hierarchy Level [Axis]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfChangesInFairValueOfLevel3LiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByLiabilityClassAxis": { "auth_ref": [ "r452", "r453" ], "lang": { "en-us": { "role": { "documentation": "Information by class of liability.", "label": "Fair Value By Liability Class [Axis]", "terseLabel": "Liability Class" } } }, "localname": "FairValueByLiabilityClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfChangesInFairValueOfLevel3LiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r444", "r445", "r448", "r449", "r454" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Fair Value By Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r258", "r327", "r329", "r334", "r342", "r445", "r505" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value Inputs Level1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r258", "r272", "r273", "r327", "r329", "r334", "r342", "r445", "r506" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value Inputs Level2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r258", "r272", "r273", "r327", "r329", "r330", "r331", "r332", "r333", "r334", "r342", "r445", "r507" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value Inputs Level3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfChangesInFairValueOfLevel3LiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "auth_ref": [ "r450" ], "lang": { "en-us": { "role": { "documentation": "Represents classes of liabilities measured and disclosed at fair value.", "label": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation By Liability Class [Domain]", "terseLabel": "Fair Value by Liability Class" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfChangesInFairValueOfLevel3LiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation Calculation Roll Forward" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]", "terseLabel": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfChangesInFairValueOfLevel3LiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "auth_ref": [ "r450", "r453" ], "lang": { "en-us": { "role": { "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.", "label": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]", "terseLabel": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfChangesInFairValueOfLevel3LiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r450", "r453" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Text Block]", "terseLabel": "Summary of Changes in Fair Value of Level 3 Liabilities" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Fair Value Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement Policy Policy [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "auth_ref": [ "r451" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).", "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings", "terseLabel": "Change in fair value of warrant liability" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfChangesInFairValueOfLevel3LiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r450" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value", "periodEndLabel": "Balance", "periodStartLabel": "Balance" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfChangesInFairValueOfLevel3LiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r258", "r272", "r273", "r327", "r329", "r330", "r331", "r332", "r333", "r334", "r342", "r505", "r506", "r507" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Measurements Fair Value Hierarchy [Domain]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfChangesInFairValueOfLevel3LiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r452", "r454" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value Measurements Recurring [Member]", "terseLabel": "Fair Value, Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinanceLeaseInterestExpense": { "auth_ref": [ "r472", "r479", "r488" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesComponentsOfLeaseExpenseDetails": { "order": 10020.0, "parentTag": "dmtk_FinanceLeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense on finance lease liability.", "label": "Finance Lease Interest Expense", "terseLabel": "Finance lease interest expense" } } }, "localname": "FinanceLeaseInterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesComponentsOfLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiability": { "auth_ref": [ "r471", "r487" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfLongTermFinanceLeaseObligationsDetails": { "order": 10040.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.", "label": "Finance Lease Liability", "totalLabel": "Present value of net minimum lease payments" } } }, "localname": "FinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfLongTermFinanceLeaseObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Finance Lease Liability [Abstract]" } } }, "localname": "FinanceLeaseLiabilityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FinanceLeaseLiabilityCurrent": { "auth_ref": [ "r471" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfLongTermFinanceLeaseObligationsDetails": { "order": 10010.0, "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0 }, "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10170.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.", "label": "Finance Lease Liability Current", "negatedLabel": "Less: current portion of finance lease obligations", "terseLabel": "Current portion of finance lease obligations" } } }, "localname": "FinanceLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfLongTermFinanceLeaseObligationsDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "auth_ref": [ "r471" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfLongTermFinanceLeaseObligationsDetails": { "order": 10020.0, "parentTag": "us-gaap_FinanceLeaseLiability", "weight": 1.0 }, "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10100.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.", "label": "Finance Lease Liability Noncurrent", "terseLabel": "Long-term finance lease obligations, less current portion" } } }, "localname": "FinanceLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfLongTermFinanceLeaseObligationsDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "auth_ref": [ "r487" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfLongTermFinanceLeaseObligationsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.", "label": "Finance Lease Liability Payments Due", "totalLabel": "Gross finance lease obligations" } } }, "localname": "FinanceLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfLongTermFinanceLeaseObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r487" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails": { "order": 10120.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease Liability Payments Due After Year Five", "terseLabel": "Finance lease obligations, including interest payments due thereafter" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r487" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails": { "order": 10070.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease Liability Payments Due Next Twelve Months", "terseLabel": "Finance lease obligations, including interest payments due in 2022" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r487" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails": { "order": 10110.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease Liability Payments Due Year Five", "terseLabel": "Finance lease obligations, including interest payments due in 2026" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r487" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails": { "order": 10100.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease Liability Payments Due Year Four", "terseLabel": "Finance lease obligations, including interest payments due in 2025" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r487" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails": { "order": 10090.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease Liability Payments Due Year Three", "terseLabel": "Finance lease obligations, including interest payments due in 2024" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r487" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails": { "order": 10080.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease Liability Payments Due Year Two", "terseLabel": "Finance lease obligations, including interest payments due in 2023" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r487" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfLongTermFinanceLeaseObligationsDetails": { "order": 10030.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.", "label": "Finance Lease Liability Undiscounted Excess Amount", "negatedLabel": "Less: imputed interest" } } }, "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfLongTermFinanceLeaseObligationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r473", "r482" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "Finance Lease Principal Payments", "terseLabel": "Financing cash flows from finance leases" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesComponentsOfLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "auth_ref": [ "r472", "r479", "r488" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesComponentsOfLeaseExpenseDetails": { "order": 10010.0, "parentTag": "dmtk_FinanceLeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.", "label": "Finance Lease Right Of Use Asset Amortization", "terseLabel": "Amortization of leased assets" } } }, "localname": "FinanceLeaseRightOfUseAssetAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesComponentsOfLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r485", "r488" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for finance lease calculated at point in time.", "label": "Finance Lease Weighted Average Discount Rate Percent", "terseLabel": "Weighted-average discount rate for finance leases" } } }, "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesComponentsOfLeaseExpenseDetails" ], "xbrltype": "percentItemType" }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r484", "r488" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Finance Lease Weighted Average Remaining Lease Term1", "terseLabel": "Weighted-average remaining lease term of finance leases (in years)" } } }, "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesComponentsOfLeaseExpenseDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r197", "r198", "r200", "r201", "r202", "r208", "r209", "r210", "r211", "r212", "r214", "r215", "r216", "r217", "r269", "r298", "r437", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r609", "r610", "r611", "r612", "r613", "r614", "r615" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfShortTermMarketableSecuritiesDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FurnitureAndFixturesGross": { "auth_ref": [ "r222" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndPPEDetails": { "order": 10050.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture And Fixtures Gross", "terseLabel": "Furniture and fixtures" } } }, "localname": "FurnitureAndFixturesGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndPPEDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnDispositionOfAssets1": { "auth_ref": [ "r97" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10330.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.", "label": "Gain Loss On Disposition Of Assets1", "negatedLabel": "Loss on disposal of equipment" } } }, "localname": "GainLossOnDispositionOfAssets1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r97", "r276", "r277" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10270.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "order": 10050.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gains Losses On Extinguishment Of Debt", "negatedLabel": "Gain on extinguishment of convertible notes", "terseLabel": "Gain on debt extinguishment of convertible notes", "verboseLabel": "Gain on debt extinguishment" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r85" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "order": 10110.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General And Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r83", "r112", "r164", "r172", "r175", "r178", "r180", "r204", "r231", "r232", "r233", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r457" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "order": 10070.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit/(loss)" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": { "auth_ref": [ "r97", "r220" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.", "label": "Impairment Of Long Lived Assets To Be Disposed Of", "terseLabel": "Impairment losses" } } }, "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r225", "r226" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r226" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r396" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r113", "r395", "r397", "r404", "r412", "r414", "r415", "r416", "r417" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r77", "r392", "r393", "r397", "r398", "r403", "r409" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax Policy [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r96" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10350.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase Decrease In Accounts Receivable", "negatedLabel": "Accounts receivable, net" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r96" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10360.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase Decrease In Inventories", "negatedLabel": "Inventory" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase Decrease In Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "auth_ref": [ "r96", "r482" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10380.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation for operating lease.", "label": "Increase Decrease In Operating Lease Liability", "terseLabel": "Operating lease liabilities, net" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r96" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10370.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase Decrease In Prepaid Deferred Expense And Other Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "auth_ref": [], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "order": 10030.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of nonoperating interest income (expense).", "label": "Interest Income Expense Nonoperating Net", "terseLabel": "Interest income, net" } } }, "localname": "InterestIncomeExpenseNonoperatingNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which reported facts about interest income have been included.", "label": "Interest Income [Member]", "terseLabel": "Interest Income, Net" } } }, "localname": "InterestIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r91", "r94", "r101" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid Net", "terseLabel": "Cash paid for interest on finance lease obligations" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r5", "r58", "r499" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10260.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory Net", "terseLabel": "Inventory" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentHoldingsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Investment Holdings [Line Items]", "terseLabel": "Investment Holdings [Line Items]" } } }, "localname": "InvestmentHoldingsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfShortTermMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentHoldingsTable": { "auth_ref": [ "r590", "r591", "r592", "r593" ], "lang": { "en-us": { "role": { "documentation": "The investment holdings table is used for any listing of investments. The \"Investment [Axis]\" identifies the investment for which the line items apply. The other axes are used for categorizing the investments and creating useful subtotals. These axes cover different categorizations. The appropriate axes are expected to be used. Additional axes can be added for alternative categorizations.", "label": "Investment Holdings [Table]", "terseLabel": "Investment Holdings [Table]" } } }, "localname": "InvestmentHoldingsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfShortTermMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments Fair Value Disclosure [Abstract]", "terseLabel": "Marketable securities, available for sale:" } } }, "localname": "InvestmentsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseCostAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lease Cost [Abstract]" } } }, "localname": "LeaseCostAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r486" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease Cost Table [Text Block]", "terseLabel": "Components of Lease Expense" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseExpirationDate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format.", "label": "Lease Expiration Date1", "terseLabel": "Lease expiration date" } } }, "localname": "LeaseExpirationDate1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "us-gaap_LeaseholdImprovementsGross": { "auth_ref": [ "r13", "r222" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndPPEDetails": { "order": 10060.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements Gross", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndPPEDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r475" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee Leases Policy [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseDescription": { "auth_ref": [ "r476" ], "lang": { "en-us": { "role": { "documentation": "Description of lessee's operating lease.", "label": "Lessee Operating Lease Description", "terseLabel": "Lessee, operating lease, description" } } }, "localname": "LesseeOperatingLeaseDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseDiscountRate": { "auth_ref": [ "r478" ], "lang": { "en-us": { "role": { "documentation": "Discount rate used by lessee to determine present value of operating lease payments.", "label": "Lessee Operating Lease Discount Rate", "terseLabel": "Estimated discount rate" } } }, "localname": "LesseeOperatingLeaseDiscountRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r487" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee Operating Lease Liability Payments Due", "terseLabel": "Estimated future lease payment obligation", "totalLabel": "Operating lease obligations, including interest payments due, Total" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r487" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails": { "order": 10180.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due After Year Five", "terseLabel": "Operating lease obligations, including interest payments due thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r487" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails": { "order": 10130.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Next Twelve Months", "terseLabel": "Operating lease obligations, including interest payments due in 2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r487" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails": { "order": 10170.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Year Five", "terseLabel": "Operating lease obligations, including interest payments due in 2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r487" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails": { "order": 10160.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Year Four", "terseLabel": "Operating lease obligations, including interest payments due in 2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r487" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails": { "order": 10150.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Year Three", "terseLabel": "Operating lease obligations, including interest payments due in 2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r487" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails": { "order": 10140.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Year Two", "terseLabel": "Operating lease obligations, including interest payments due in 2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesScheduleOfFutureMinimumLeasePaymentsUnderOperatingAndFinanceLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseOptionToExtend": { "auth_ref": [ "r477" ], "lang": { "en-us": { "role": { "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.", "label": "Lessee Operating Lease Option To Extend", "terseLabel": "Option to extend the lease term" } } }, "localname": "LesseeOperatingLeaseOptionToExtend", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": { "auth_ref": [ "r476" ], "lang": { "en-us": { "role": { "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee Operating Lease Remaining Lease Term", "terseLabel": "Remaining lease term" } } }, "localname": "LesseeOperatingLeaseRemainingLeaseTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LetterOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).", "label": "Letter Of Credit [Member]", "terseLabel": "Letter of Credit" } } }, "localname": "LetterOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LettersOfCreditOutstandingAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.", "label": "Letters Of Credit Outstanding Amount", "terseLabel": "Letters of credit" } } }, "localname": "LettersOfCreditOutstandingAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r46", "r112", "r174", "r204", "r231", "r232", "r233", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r424", "r427", "r428", "r457", "r497", "r498" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfImpactOfConsolidatedBalanceSheetsFromAdjustmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10010.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfImpactOfConsolidatedBalanceSheetsFromAdjustmentDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r36", "r112", "r204", "r457", "r499", "r552", "r568" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities And Stockholders Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities And Stockholders Equity [Abstract]", "terseLabel": "Liabilities and Stockholders\u2019 Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r49", "r112", "r204", "r231", "r232", "r233", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r424", "r427", "r428", "r457", "r497", "r498", "r499" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10070.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r444" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Liabilities Fair Value Disclosure", "totalLabel": "Total liabilities measured at fair value on a recurring basis" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities Fair Value Disclosure [Abstract]", "terseLabel": "Liabilities:" } } }, "localname": "LiabilitiesFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities Noncurrent [Abstract]", "terseLabel": "Long term liabilities:" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfImpactOfConsolidatedBalanceSheetsFromAdjustmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilityForUncertainTaxPositionsCurrent": { "auth_ref": [ "r48" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount recognized for uncertainty in income taxes classified as current.", "label": "Liability For Uncertain Tax Positions Current", "terseLabel": "Uncertain tax positions" } } }, "localname": "LiabilityForUncertainTaxPositionsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r53" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Longterm Debt Type [Axis]", "terseLabel": "Long-term Debt, Type" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r53", "r230" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Longterm Debt Type [Domain]", "terseLabel": "Long-term Debt, Type" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_MachineryAndEquipmentGross": { "auth_ref": [ "r13", "r222" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndPPEDetails": { "order": 10030.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Machinery And Equipment Gross", "terseLabel": "Laboratory equipment" } } }, "localname": "MachineryAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndPPEDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesCurrent": { "auth_ref": [ "r7", "r47" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10240.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security, classified as current.", "label": "Marketable Securities Current", "terseLabel": "Short-term marketable securities" } } }, "localname": "MarketableSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesPolicy": { "auth_ref": [ "r559" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment classified as marketable security.", "label": "Marketable Securities Policy", "terseLabel": "Marketable Securities" } } }, "localname": "MarketableSecuritiesPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_MeasurementInputExpectedDividendRateMember": { "auth_ref": [ "r447" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.", "label": "Measurement Input Expected Dividend Rate [Member]", "terseLabel": "Expected Dividend Yield" } } }, "localname": "MeasurementInputExpectedDividendRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAssumptionsUsedToCalculateFairValueOfWarrantLiabilityUsingBlackScholesMertonValuationModelDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedTermMember": { "auth_ref": [ "r447" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.", "label": "Measurement Input Expected Term [Member]", "terseLabel": "Expected Term" } } }, "localname": "MeasurementInputExpectedTermMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAssumptionsUsedToCalculateFairValueOfWarrantLiabilityUsingBlackScholesMertonValuationModelDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputPriceVolatilityMember": { "auth_ref": [ "r447" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.", "label": "Measurement Input Price Volatility [Member]", "terseLabel": "Assumed Volatility" } } }, "localname": "MeasurementInputPriceVolatilityMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAssumptionsUsedToCalculateFairValueOfWarrantLiabilityUsingBlackScholesMertonValuationModelDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "auth_ref": [ "r447" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.", "label": "Measurement Input Risk Free Interest Rate [Member]", "terseLabel": "Assumed Risk-free Interest Rate" } } }, "localname": "MeasurementInputRiskFreeInterestRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAssumptionsUsedToCalculateFairValueOfWarrantLiabilityUsingBlackScholesMertonValuationModelDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r447" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]", "terseLabel": "Measurement Input Type" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAssumptionsUsedToCalculateFairValueOfWarrantLiabilityUsingBlackScholesMertonValuationModelDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]", "terseLabel": "Measurement Input Type" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAssumptionsUsedToCalculateFairValueOfWarrantLiabilityUsingBlackScholesMertonValuationModelDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MunicipalNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Short-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments.", "label": "Municipal Notes [Member]", "terseLabel": "Municipal Securities" } } }, "localname": "MunicipalNotesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfShortTermMarketableSecuritiesDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r93" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10030.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided By Used In Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r93" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10020.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided By Used In Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r93", "r95", "r98" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10010.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided By Used In Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r2", "r72", "r74", "r80", "r81", "r98", "r112", "r122", "r124", "r125", "r127", "r128", "r132", "r133", "r138", "r164", "r172", "r175", "r178", "r180", "r204", "r231", "r232", "r233", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r443", "r457", "r555", "r571" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss": { "order": 10010.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income Loss", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfImpactOfConsolidatedStatementsOfOperationsFromAdjustmentDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements Policy Policy [Text Block]", "terseLabel": "Accounting Pronouncement Recently Adopted" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncash Investing And Financing Items [Abstract]", "terseLabel": "Supplemental disclosure of noncash investing and financing activities:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1": { "auth_ref": [ "r102", "r103", "r104" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of fixed assets that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Noncash Or Part Noncash Acquisition Fixed Assets Acquired1", "terseLabel": "Property and equipment acquired under finance leases" } } }, "localname": "NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r86" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "order": 10020.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income Expense", "terseLabel": "Total other income/(expense)", "totalLabel": "Total other expense" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfImpactOfConsolidatedStatementsOfOperationsFromAdjustmentDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income Expense [Abstract]", "terseLabel": "Other income/(expense):" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfImpactOfConsolidatedStatementsOfOperationsFromAdjustmentDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r161" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number Of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "order": 10080.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r164", "r172", "r175", "r178", "r180" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "order": 10010.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income Loss", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r480", "r488" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesComponentsOfLeaseExpenseDetails": { "order": 10030.0, "parentTag": "dmtk_OperatingLeaseCosts", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease Cost", "terseLabel": "Operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesComponentsOfLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r471" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease Liability", "terseLabel": "Lease liability" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r471" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10160.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease Liability Current", "terseLabel": "Current portion of operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r471" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10110.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease Liability Noncurrent", "terseLabel": "Operating lease liabilities, long-term" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r474", "r482" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease Payments", "terseLabel": "Operating cash flows from operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesComponentsOfLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r470" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10200.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease Right Of Use Asset", "terseLabel": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "auth_ref": [ "r97" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10300.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for right-of-use asset from operating lease.", "label": "Operating Lease Right Of Use Asset Amortization Expense", "terseLabel": "Amortization of operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r485", "r488" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease Weighted Average Discount Rate Percent", "terseLabel": "Weighted-average discount rate for operating leases" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesComponentsOfLeaseExpenseDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r484", "r488" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease Weighted Average Remaining Lease Term1", "terseLabel": "Weighted-average remaining lease term of operating leases (in years)" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesComponentsOfLeaseExpenseDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r405" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Operating Loss Carryforwards", "terseLabel": "Operating loss carryforwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwardsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Loss Carryforwards [Line Items]", "terseLabel": "Operating Loss Carryforwards [Line Items]" } } }, "localname": "OperatingLossCarryforwardsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLossCarryforwardsTable": { "auth_ref": [ "r406" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.", "label": "Operating Loss Carryforwards [Table]", "terseLabel": "Operating Loss Carryforwards [Table]" } } }, "localname": "OperatingLossCarryforwardsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization Consolidation And Presentation Of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r3", "r117", "r160", "r431" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.", "label": "Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies [Text Block]", "terseLabel": "The Company and a Summary of its Significant Accounting Policies" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r14", "r15", "r16", "r48" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfAccruedCompensationAndAccruedLiabilitiesDetails": { "order": 10020.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities Current", "terseLabel": "Other accrued expenses" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfAccruedCompensationAndAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r59", "r499" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndPPEDetails": { "order": 10120.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets Current", "terseLabel": "Other current assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndPPEDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r44" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10220.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r66", "r69" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss": { "order": 10020.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax", "terseLabel": "Unrealized loss on available-for-sale marketable securities", "verboseLabel": "Unrealized loss on available-for-sale securities" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherExpenseMember": { "auth_ref": [ "r435" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other expense.", "label": "Other Expense [Member]", "terseLabel": "Other Expense" } } }, "localname": "OtherExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r90" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10090.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments Of Stock Issuance Costs", "negatedLabel": "Payments of issuance costs in connection with Form S-1 registration statement", "verboseLabel": "Preferred stock, issuance costs" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "auth_ref": [ "r192" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10200.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for purchase of marketable security.", "label": "Payments To Acquire Marketable Securities", "negatedLabel": "Purchases of marketable securities" } } }, "localname": "PaymentsToAcquireMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r87" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10230.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments To Acquire Property Plant And Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "auth_ref": [ "r326", "r328", "r334", "r335", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r350" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for retirement benefits.", "label": "Pension And Other Postretirement Benefits Disclosure [Text Block]", "terseLabel": "Retirement Plan" } } }, "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureRetirementPlan" ], "xbrltype": "textBlockItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r354", "r381" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAssumptionsUsedToDetermineFairValueOfEachOptionOnDateOfGrantIssuedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAssumptionsUsedToDetermineFairValueOfEachOptionOnDateOfGrantIssuedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r28", "r284" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock Par Or Stated Value Per Share", "verboseLabel": "Preferred stock, par value per share" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r28" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock Shares Authorized", "verboseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r28" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock Shares Outstanding", "verboseLabel": "Convertible preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r9", "r38", "r39" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndPPEDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10270.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense And Other Assets Current", "terseLabel": "Prepaid expenses and other current assets", "totalLabel": "Total prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndPPEDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Prepaid Expense And Other Assets Current [Abstract]", "terseLabel": "Prepaid expenses and other current assets:" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndPPEDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PrepaidInsurance": { "auth_ref": [ "r8", "r10", "r218", "r219" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndPPEDetails": { "order": 10070.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Insurance", "terseLabel": "Prepaid insurance" } } }, "localname": "PrepaidInsurance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndPPEDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PriorPeriodAdjustmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Prior Period Adjustment [Abstract]" } } }, "localname": "PriorPeriodAdjustmentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PrivatePlacementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.", "label": "Private Placement [Member]", "terseLabel": "Private Placement" } } }, "localname": "PrivatePlacementMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromConvertibleDebt": { "auth_ref": [ "r89" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10150.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Proceeds From Convertible Debt", "terseLabel": "Proceeds from convertible notes payable", "verboseLabel": "Proceeds from issuance of convertible note" } } }, "localname": "ProceedsFromConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r88" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10040.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds From Issuance Of Common Stock", "positiveLabel": "Net proceeds from issuance of common stock", "terseLabel": "Proceeds from issuance of common stock", "verboseLabel": "Gross proceeds from issuance of equity securities" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": { "auth_ref": [ "r88" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10060.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.", "label": "Proceeds From Issuance Of Convertible Preferred Stock", "verboseLabel": "Proceeds from issuance of Convertible Preferred Stock" } } }, "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfDebt": { "auth_ref": [ "r89" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.", "label": "Proceeds From Issuance Of Debt", "terseLabel": "Proceeds from issuance of convertible note" } } }, "localname": "ProceedsFromIssuanceOfDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureDebtAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": { "auth_ref": [ "r88" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.", "label": "Proceeds From Issuance Of Private Placement", "terseLabel": "Gross proceeds from PIPE financing" } } }, "localname": "ProceedsFromIssuanceOfPrivatePlacement", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingencieAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "auth_ref": [ "r88" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.", "label": "Proceeds From Issuance Or Sale Of Equity", "terseLabel": "Proceeds from equity financing" } } }, "localname": "ProceedsFromIssuanceOrSaleOfEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingencieAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfNotesPayable": { "auth_ref": [], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10160.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from long-term debt supported by a written promise to pay an obligation.", "label": "Proceeds From Repayments Of Notes Payable", "terseLabel": "Payments of notes payable" } } }, "localname": "ProceedsFromRepaymentsOfNotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10220.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.", "label": "Proceeds From Sale And Maturity Of Marketable Securities", "terseLabel": "Maturities of marketable securities" } } }, "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r88", "r382" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10130.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds From Stock Options Exercised", "terseLabel": "Proceeds from exercise of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockPlans": { "auth_ref": [ "r88" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10140.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from the stock plan during the period.", "label": "Proceeds From Stock Plans", "terseLabel": "Proceeds from contributions to the employee stock purchase plan" } } }, "localname": "ProceedsFromStockPlans", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromWarrantExercises": { "auth_ref": [ "r88" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10120.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.", "label": "Proceeds From Warrant Exercises", "terseLabel": "Proceeds from exercise of common stock warrants" } } }, "localname": "ProceedsFromWarrantExercises", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductAndServiceOtherMember": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other.", "label": "Product And Service Other [Member]", "terseLabel": "Contract Revenue, Other" } } }, "localname": "ProductAndServiceOtherMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesScheduleOfRevenuesDisaggregatedByRevenueSourceDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProductInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Product Information [Line Items]", "terseLabel": "Product Information [Line Items]" } } }, "localname": "ProductInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfPercentagesOfTotalRevenueOrAccountsReceivableForThirdPartyPayersAndPharmaceuticalCustomersDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfPercentagesOfTotalRevenueOrAccountsReceivableForThirdPartyPayersAndPharmaceuticalCustomersParentheticalDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r2", "r72", "r74", "r80", "r92", "r112", "r122", "r132", "r133", "r164", "r172", "r175", "r178", "r180", "r204", "r231", "r232", "r233", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r422", "r425", "r426", "r429", "r430", "r443", "r457", "r557" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10240.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Profit Loss", "terseLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r43", "r224" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property Plant And Equipment By Type [Axis]", "terseLabel": "Long-Lived Tangible Asset" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisposals": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of divestiture of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property Plant And Equipment Disposals", "terseLabel": "Disposal of plant or equipment" } } }, "localname": "PropertyPlantAndEquipmentDisposals", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r42", "r222" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndPPEDetails": { "order": 10010.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property Plant And Equipment Gross", "terseLabel": "Gross assets", "totalLabel": "Total property and equipment, gross", "verboseLabel": "Gross assets" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndPPEDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentGrossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property Plant And Equipment Gross [Abstract]", "terseLabel": "Property and equipment, gross:" } } }, "localname": "PropertyPlantAndEquipmentGrossAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndPPEDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r18", "r19", "r224", "r499", "r560", "r569" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndPPEDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10190.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property Plant And Equipment Net", "terseLabel": "Property and equipment, net", "totalLabel": "Total property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfPrepaidExpensesAndPPEDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r41", "r224", "r596", "r597" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property Plant And Equipment Policy [Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r18", "r222" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property Plant And Equipment Type [Domain]", "terseLabel": "Long-Lived Tangible Asset" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property Plant And Equipment Useful Life", "terseLabel": "Useful life of the assets" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ReceivablesPolicyTextBlock": { "auth_ref": [ "r186", "r188", "r189", "r190" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.", "label": "Receivables Policy [Text Block]", "terseLabel": "Accounts Receivable" } } }, "localname": "ReceivablesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r336", "r491", "r492" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r336", "r491", "r492", "r494" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]", "terseLabel": "Related Party Transaction" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r336" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]", "terseLabel": "Related Party Transaction" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": { "auth_ref": [ "r491" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.", "label": "Related Party Transaction Expenses From Transactions With Related Party", "terseLabel": "Related party transaction, other" } } }, "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of selling, general and administrative expenses resulting from transactions, excluding transactions that are eliminated in consolidated or combined financial statements, with related party.", "label": "Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party", "terseLabel": "Related party certain marketing cost" } } }, "localname": "RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r336", "r491", "r494", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party Transactions By Related Party [Axis]", "terseLabel": "Related Party" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r489", "r490", "r492", "r495", "r496" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfDebtAndCapitalLeaseObligations": { "auth_ref": [], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10180.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for short-term and long-term debt and lease obligation.", "label": "Repayments Of Debt And Capital Lease Obligations", "negatedLabel": "Principal repayments of finance lease obligations" } } }, "localname": "RepaymentsOfDebtAndCapitalLeaseObligations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r391", "r533", "r600" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "order": 10100.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research And Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r391" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research And Development Expense Policy", "terseLabel": "Research and Development" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedCashNoncurrent": { "auth_ref": [ "r12", "r20", "r105", "r594" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": { "order": 10030.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 }, "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10210.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash Noncurrent", "periodEndLabel": "Restricted cash, end of period", "periodStartLabel": "Restricted cash, beginning of period", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units R S U [Member]", "terseLabel": "Restricted Stock Units" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetail", "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfRestrictedStockUnitsAwardTransactionsDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r32", "r308", "r386", "r499", "r567", "r581", "r586" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10060.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings Accumulated Deficit", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfImpactOfConsolidatedBalanceSheetsFromAdjustmentDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r118", "r119", "r120", "r123", "r130", "r133", "r205", "r383", "r384", "r385", "r410", "r411", "r441", "r577", "r579" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r162", "r163", "r171", "r176", "r177", "r181", "r182", "r183", "r315", "r316", "r534" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue From Contract With Customer Excluding Assessed Tax", "terseLabel": "Total revenues" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesScheduleOfRevenuesDisaggregatedByRevenueSourceDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "auth_ref": [ "r162", "r163", "r171", "r176", "r177", "r181", "r182", "r183", "r315", "r316", "r534" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "order": 10120.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.", "label": "Revenue From Contract With Customer Including Assessed Tax", "terseLabel": "Total revenues" } } }, "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r106", "r107" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue Recognition Policy [Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRemainingPerformanceObligation": { "auth_ref": [ "r313" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.", "label": "Revenue Remaining Performance Obligation", "terseLabel": "Remaining performance obligation, estimated revenue expected to be recognized" } } }, "localname": "RevenueRemainingPerformanceObligation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails1" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": { "auth_ref": [ "r314" ], "lang": { "en-us": { "role": { "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1", "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails1" ], "xbrltype": "durationItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenues:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": { "auth_ref": [ "r483", "r488" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.", "label": "Right Of Use Asset Obtained In Exchange For Finance Lease Liability", "terseLabel": "Right-of-use assets obtained in exchange for new finance lease obligations" } } }, "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesComponentsOfLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r483", "r488" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right Of Use Asset Obtained In Exchange For Operating Lease Liability", "terseLabel": "Right-of-use assets obtained in exchange for lease obligations" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesComponentsOfLeaseExpenseDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale Of Stock Name Of Transaction [Domain]", "terseLabel": "Sale of Stock" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale Of Stock Number Of Shares Issued In Transaction", "positiveLabel": "Issuance of stock" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale Of Stock Price Per Share", "positiveLabel": "Public offering price" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r155", "r183" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Sales Revenue Net [Member]", "terseLabel": "Total Revenue" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfPercentagesOfTotalRevenueOrAccountsReceivableForThirdPartyPayersAndPharmaceuticalCustomersDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfPercentagesOfTotalRevenueOrAccountsReceivableForThirdPartyPayersAndPharmaceuticalCustomersParentheticalDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.", "label": "Schedule Of Accounts Payable And Accrued Liabilities Table [Text Block]", "terseLabel": "Schedule of Accrued Compensation and Accrued Liabilities" } } }, "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of cash and cash equivalents.", "label": "Schedule Of Cash And Cash Equivalents Table [Text Block]", "terseLabel": "Summary of Reconciliation of Cash, Cash Equivalents and Restricted Cash" } } }, "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r402" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]", "terseLabel": "Schedule of Deferred Tax Assets and Liabilities from Federal and State income Taxes" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r394" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]", "terseLabel": "Schedule of Reconciliation of Income Tax Rate" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable": { "auth_ref": [ "r124", "r125", "r126", "r129", "r130", "r132", "r133", "r144" ], "lang": { "en-us": { "role": { "documentation": "Schedule of prior period adjustments to correct an error in previously issued financial statements. The disclosure may include, but is not limited to: (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustment (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made. This table can be used to disclose the amounts as previously reported and the effect of the correction or other adjustment on per line item or per share amount basis. This table uses as its line items financial statement line items that are affected by prior period adjustments.", "label": "Schedule Of Error Corrections And Prior Period Adjustment Restatement [Table]", "terseLabel": "Schedule Of Error Corrections And Prior Period Adjustment Restatement [Table]" } } }, "localname": "ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfImpactOfConsolidatedBalanceSheetsFromAdjustmentDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfImpactOfConsolidatedStatementsOfOperationsFromAdjustmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock": { "auth_ref": [ "r131", "r132", "r133" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made.", "label": "Schedule Of Error Corrections And Prior Period Adjustments [Text Block]", "terseLabel": "Schedule of Revision to Prior Period Financial Statements" } } }, "localname": "ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r444", "r445" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block]", "terseLabel": "Summary of Assets Measured at Fair Value On Recurring Basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfProductInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule detailing quantitative information concerning products or product lines by product or product line.", "label": "Schedule Of Product Information [Table]", "terseLabel": "Schedule Of Product Information [Table]" } } }, "localname": "ScheduleOfProductInformationTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfPercentagesOfTotalRevenueOrAccountsReceivableForThirdPartyPayersAndPharmaceuticalCustomersDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfPercentagesOfTotalRevenueOrAccountsReceivableForThirdPartyPayersAndPharmaceuticalCustomersParentheticalDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfProductInformationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of product information that are included in the discussion of the nature of an entity's operations.", "label": "Schedule Of Product Information Table [Text Block]", "terseLabel": "Summary of Percentages of Total Revenue or Accounts Receivable for Third Party Payers and Pharmaceutical Customers" } } }, "localname": "ScheduleOfProductInformationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r493", "r494" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule Of Related Party Transactions By Related Party [Table]", "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r354", "r381" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]", "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfRestrictedStockUnitsAwardTransactionsDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfStockOptionsTransactionsDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAssumptionsUsedToDetermineFairValueOfEachOptionOnDateOfGrantIssuedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "auth_ref": [ "r360" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.", "label": "Schedule Of Share Based Compensation Restricted Stock Units Award Activity Table [Text Block]", "terseLabel": "Summary of Restricted Stock units Award Transactions" } } }, "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r360", "r370", "r371" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]", "terseLabel": "Summary of Stock Options transactions" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r373" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]", "terseLabel": "Assumptions Used to Estimate Fair Value of Each Option for Employees on Date of Grant" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r54", "r109", "r146", "r147", "r280", "r282", "r283", "r284", "r285", "r286", "r287", "r289", "r293", "r298", "r301", "r302", "r303", "r305", "r306", "r307", "r308" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule Of Stock By Class [Table]", "terseLabel": "Schedule Of Stock By Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetail", "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceParentheticalDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTextBlock": { "auth_ref": [ "r27", "r28", "r29", "r281", "r282", "r283", "r301", "r302", "r303", "r305", "r306", "r307", "r308" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.", "label": "Schedule Of Stock By Class [Text Block]", "terseLabel": "Summary of Common Stock Reserved for Future Issuance" } } }, "localname": "ScheduleOfStockByClassTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SecurityDeposit": { "auth_ref": [ "r60" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.", "label": "Security Deposit", "terseLabel": "Security deposit" } } }, "localname": "SecurityDeposit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r165", "r166", "r167", "r168", "r169", "r170", "r182" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting Policy Policy [Text Block]", "terseLabel": "Segment Reporting" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingAndMarketingExpense": { "auth_ref": [], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "order": 10090.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.", "label": "Selling And Marketing Expense", "terseLabel": "Sales and marketing" } } }, "localname": "SellingAndMarketingExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r96" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10310.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share Based Compensation", "terseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": { "auth_ref": [ "r355" ], "lang": { "en-us": { "role": { "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Requisite Service Period1", "terseLabel": "Requisite service period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r365" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period", "negatedLabel": "Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfRestrictedStockUnitsAwardTransactionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r369" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value", "terseLabel": "Forfeited, Weighted average grant date fair value per share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfRestrictedStockUnitsAwardTransactionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r367" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period", "terseLabel": "Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfRestrictedStockUnitsAwardTransactionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r367" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value", "terseLabel": "Granted, Weighted average grant date fair value per share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfRestrictedStockUnitsAwardTransactionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r366" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfRestrictedStockUnitsAwardTransactionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r366" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value", "periodEndLabel": "Ending balance, Weighted average grant date fair value per share", "periodStartLabel": "Beginning balance, Weighted average grant date fair value per share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfRestrictedStockUnitsAwardTransactionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r368" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period", "negatedLabel": "Released" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfRestrictedStockUnitsAwardTransactionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r368" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value", "terseLabel": "Released, Weighted average grant date fair value per share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfRestrictedStockUnitsAwardTransactionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r376" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate", "terseLabel": "Expected dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAssumptionsUsedToDetermineFairValueOfEachOptionOnDateOfGrantIssuedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r375" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate", "terseLabel": "Assumed volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAssumptionsUsedToDetermineFairValueOfEachOptionOnDateOfGrantIssuedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum", "terseLabel": "Assumed volatility,maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAssumptionsUsedToDetermineFairValueOfEachOptionOnDateOfGrantIssuedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum", "terseLabel": "Assumed volatility,minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAssumptionsUsedToDetermineFairValueOfEachOptionOnDateOfGrantIssuedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r377" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate", "terseLabel": "Assumed risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAssumptionsUsedToDetermineFairValueOfEachOptionOnDateOfGrantIssuedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum", "terseLabel": "Assumed risk-free interest rate,maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAssumptionsUsedToDetermineFairValueOfEachOptionOnDateOfGrantIssuedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum", "terseLabel": "Assumed risk-free interest rate,minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAssumptionsUsedToDetermineFairValueOfEachOptionOnDateOfGrantIssuedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]", "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]", "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfRestrictedStockUnitsAwardTransactionsDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfStockOptionsTransactionsDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAssumptionsUsedToDetermineFairValueOfEachOptionOnDateOfGrantIssuedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r357" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized", "terseLabel": "Common stock initially reserved for issuance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r381" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant", "terseLabel": "Options remain available for future grant" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number", "terseLabel": "Options exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfStockOptionsTransactionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price", "terseLabel": "Options exercisable, Weighted average exercise price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfStockOptionsTransactionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r365" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period", "negatedLabel": "Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfStockOptionsTransactionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross", "terseLabel": "Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfStockOptionsTransactionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r381" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value", "terseLabel": "Aggregate intrinsic value, outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfStockOptionsTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r362", "r381" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfStockOptionsTransactionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price", "periodEndLabel": "Weighted average exercise, Ending balance", "periodStartLabel": "Weighted average exercise, Beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfStockOptionsTransactionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r371" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value", "terseLabel": "Options vested and expected to vest, Aggregate intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfStockOptionsTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r372" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number", "terseLabel": "Options vested and expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfStockOptionsTransactionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r372" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price", "terseLabel": "Options vested and expected to vest, Weighted average exercise price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfStockOptionsTransactionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r352", "r358" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]", "terseLabel": "Award Type" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceDetail", "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfRestrictedStockUnitsAwardTransactionsDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfStockOptionsTransactionsDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price", "terseLabel": "Weighted average exercise, Exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfStockOptionsTransactionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price", "terseLabel": "Weighted average exercise, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfStockOptionsTransactionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price", "terseLabel": "Weighted average exercise Granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfStockOptionsTransactionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r354", "r359" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share Based Compensation Option And Incentive Plans Policy", "terseLabel": "Stock-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Issuance price per share" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r356" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period", "terseLabel": "Contractual term of options granted" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r374", "r387" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1", "terseLabel": "Expected option term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAssumptionsUsedToDetermineFairValueOfEachOptionOnDateOfGrantIssuedDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r381" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1", "terseLabel": "Options exercisable, Aggregate intrinsic value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfStockOptionsTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r381" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1", "terseLabel": "Options exercisable, Weighted average remaining contractual term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfStockOptionsTransactionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r372" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2", "terseLabel": "Weighted average remaining contractual term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfStockOptionsTransactionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r372" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1", "terseLabel": "Options vested and expected to vest, Weighted average remaining contractual term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfStockOptionsTransactionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase price of common stock expressed as a percentage of its fair value.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent", "terseLabel": "Options granted, exercise price expressed as a percentage of fair market value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r300" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Shares Issued", "verboseLabel": "Shares, issued" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares Issued Price Per Share", "terseLabel": "Issuance price per share" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares Outstanding", "periodEndLabel": "Balance, Shares", "periodStartLabel": "Balance, Shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StandbyLettersOfCreditMember": { "auth_ref": [ "r228", "r229", "r421", "r589" ], "lang": { "en-us": { "role": { "documentation": "An irrevocable undertaking (typically by a financial institution) to guarantee payment of a specified financial obligation.", "label": "Standby Letters Of Credit [Member]", "terseLabel": "Standby Letter of Credit" } } }, "localname": "StandbyLettersOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State And Local Jurisdiction [Member]", "terseLabel": "State and local jurisdiction" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r27", "r28", "r29", "r109", "r112", "r135", "r136", "r137", "r139", "r141", "r146", "r147", "r148", "r204", "r231", "r235", "r236", "r237", "r240", "r241", "r284", "r285", "r289", "r293", "r300", "r457", "r609" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Statement Class Of Stock [Axis]", "terseLabel": "Class of Stock" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r57", "r78", "r79", "r80", "r118", "r119", "r120", "r123", "r130", "r133", "r145", "r205", "r300", "r308", "r383", "r384", "r385", "r410", "r411", "r441", "r459", "r460", "r461", "r462", "r463", "r464", "r577", "r578", "r579", "r620" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Statement Equity Components [Axis]", "terseLabel": "Equity Components" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfCommonStockReservedForFutureIssuanceParentheticalDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Stockholders Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r118", "r119", "r120", "r145", "r534" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r56", "r261", "r300", "r301", "r308" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Stock Issued During Period Shares Conversion Of Convertible Securities", "terseLabel": "Issuance of common stock through conversion, Shares", "verboseLabel": "Issuance of common stock through conversion, Shares" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r28", "r29", "r300", "r308" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period Shares Employee Stock Purchase Plans", "terseLabel": "Issuance of common stock from Employee Stock Purchase Plan, Shares" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r28", "r29", "r300", "r308" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period Shares New Issues", "terseLabel": "Issuance of common and preferred stock, net of issuance costs, Shares", "verboseLabel": "Preferred stock, shares issued during period" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r28", "r29", "r300", "r308" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.", "label": "Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures", "terseLabel": "Restricted stock unit release, Shares" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r28", "r29", "r300", "r308", "r364" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Stock Issued During Period Shares Stock Options Exercised", "negatedLabel": "Exercised" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquitySummaryOfStockOptionsTransactionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r57", "r300", "r308" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Stock Issued During Period Value Conversion Of Convertible Securities", "terseLabel": "Issuance of common stock through conversion" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "auth_ref": [ "r28", "r29", "r300", "r308" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.", "label": "Stock Issued During Period Value Employee Stock Purchase Plan", "terseLabel": "Issuance of common stock from Employee Stock Purchase Plan" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r28", "r29", "r300", "r308" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period Value New Issues", "terseLabel": "Issuance of common stock, net of issuance costs", "verboseLabel": "Issuance of preferred stock, total offering amount" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r29", "r34", "r35", "r112", "r187", "r204", "r457", "r499" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10020.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders Equity", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfImpactOfConsolidatedBalanceSheetsFromAdjustmentDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders Equity [Abstract]", "terseLabel": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfImpactOfConsolidatedBalanceSheetsFromAdjustmentDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders Equity Note [Abstract]" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r110", "r285", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r299", "r308", "r312" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders Equity Note Disclosure [Text Block]", "terseLabel": "Convertible Preferred Stock and Stockholders' Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": { "auth_ref": [ "r309" ], "lang": { "en-us": { "role": { "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.", "label": "Stockholders Equity Note Stock Split Conversion Ratio1", "terseLabel": "Conversion ratio of reverse stock split" } } }, "localname": "StockholdersEquityNoteStockSplitConversionRatio1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "pureItemType" }, "us-gaap_StockholdersEquityReverseStockSplit": { "auth_ref": [ "r310" ], "lang": { "en-us": { "role": { "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.", "label": "Stockholders Equity Reverse Stock Split", "terseLabel": "Description of reverse stock split of common stock" } } }, "localname": "StockholdersEquityReverseStockSplit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r500", "r501" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureSubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Subsidiary Sale Of Stock [Axis]", "terseLabel": "Sale of Stock" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "auth_ref": [ "r65" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "terseLabel": "Balance Sheet Details" } } }, "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetails" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental cash flow information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardAmount": { "auth_ref": [ "r405" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Tax Credit Carryforward Amount", "terseLabel": "Tax credit carryforwards" } } }, "localname": "TaxCreditCarryforwardAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": { "auth_ref": [ "r231", "r235", "r236", "r237", "r240", "r241" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.", "label": "Temporary Equity Carrying Amount Attributable To Parent", "periodStartLabel": "Convertible preferred stock, Balance" } } }, "localname": "TemporaryEquityCarryingAmountAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquitySharesOutstanding": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity Shares Outstanding", "periodStartLabel": "Convertible preferred stock, Balance, Shares" } } }, "localname": "TemporaryEquitySharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_TenantImprovements": { "auth_ref": [ "r570" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants.", "label": "Tenant Improvements", "terseLabel": "Tenant improvements" } } }, "localname": "TenantImprovements", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r197", "r198", "r200", "r201", "r202", "r269", "r298", "r437", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r609", "r610", "r611", "r612", "r613", "r614", "r615" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain]", "terseLabel": "Financial Instruments" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfShortTermMarketableSecuritiesDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r420" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Type Of Arrangement [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_USGovernmentAgenciesShorttermDebtSecuritiesMember": { "auth_ref": [ "r558" ], "lang": { "en-us": { "role": { "documentation": "Debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae) which have maturities of one year or less. Excludes US Treasury securities and debt issued by Government-sponsored Enterprises (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae).", "label": "U S Government Agencies Shortterm Debt Securities [Member]", "terseLabel": "U.S. Government Debt Securities" } } }, "localname": "USGovernmentAgenciesShorttermDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfShortTermMarketableSecuritiesDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r149", "r150", "r152", "r153", "r157", "r158", "r159" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use Of Estimates", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r481", "r488" ], "calculation": { "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesComponentsOfLeaseExpenseDetails": { "order": 10040.0, "parentTag": "dmtk_OperatingLeaseCosts", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable Lease Cost", "terseLabel": "Variable lease costs" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureLeasesCommitmentsAndContingenciesComponentsOfLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "terseLabel": "Common Stock Warrants" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstanding": { "auth_ref": [], "calculation": { "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10080.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.", "label": "Warrants And Rights Outstanding", "terseLabel": "Warrant liability" } } }, "localname": "WarrantsAndRightsOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "auth_ref": [ "r449" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.", "label": "Warrants And Rights Outstanding Measurement Input", "terseLabel": "Warrant liability, fair value measurement inputs" } } }, "localname": "WarrantsAndRightsOutstandingMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAssumptionsUsedToCalculateFairValueOfWarrantLiabilityUsingBlackScholesMertonValuationModelDetails" ], "xbrltype": "decimalItemType" }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "auth_ref": [ "r449" ], "lang": { "en-us": { "role": { "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Warrants And Rights Outstanding Term", "terseLabel": "Warrants expiration period", "verboseLabel": "Expected term (years)" } } }, "localname": "WarrantsAndRightsOutstandingTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/DisclosureConvertiblePreferredStockAndStockholdersEquityAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAdditionalInformationDetails", "http://dermtech.com/20211231/taxonomy/role/DisclosureTheCompanyAndSummaryOfItsSignificantAccountingPoliciesAssumptionsUsedToCalculateFairValueOfWarrantLiabilityUsingBlackScholesMertonValuationModelDetails" ], "xbrltype": "durationItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted Average Number Of Share Outstanding Basic And Diluted", "terseLabel": "Weighted average shares outstanding used in computing net loss per share, basic and diluted" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://dermtech.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 9 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r117": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765" }, "r160": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563" }, "r199": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2611-110228" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r227": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=123408193&loc=d3e12803-110250" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629" }, "r278": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r3": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 4.C)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.C)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r312": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r324": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "705", "URI": "http://asc.fasb.org/topic&trid=2122478" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "710", "URI": "http://asc.fasb.org/extlink&oid=6409733&loc=d3e19396-108361" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(l)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(o)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(p)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(q)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "http://asc.fasb.org/topic&trid=2235017" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r417": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116873149&loc=d3e923-111674" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r431": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r436": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "15", "Topic": "815", "URI": "http://asc.fasb.org/subtopic&trid=2229187" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.2)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r496": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r501": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.12)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62652-112803" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15)(b)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(f))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=66023616&loc=SL35737432-115832" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611133-123010" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611322-123010" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8,17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r601": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r602": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r603": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r604": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r605": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r606": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r607": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r608": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r609": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r610": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r611": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r612": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r613": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r614": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r615": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r616": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r617": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "848" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r65": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "210", "URI": "http://asc.fasb.org/topic&trid=2122208" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" } }, "version": "2.1" }